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Summary
Transcription of cellular genomes is the first step of gene expression, which is carried out by
DNA-dependent RNA polymerases (Pols). Pol II transcribes protein-coding genes into pre-
mRNA with the assistance of accessory factors. The conserved Paf1 complex (Paf1C) plays
multiple roles in chromatin transcription and genomic regulation. Paf1C consists of the five
subunits Paf1, Leo1, Ctr9, Cdc73, and Rtf1, and binds to the Pol II transcription elongation
complex (EC).
In this thesis I establish preparation of pure and recombinant Paf1C from the yeast
Saccharomyces cerevisiae after co-expression of its subunits in Escherichia coli. Using  a
combination of Edman sequencing and iterative truncation, I obtained a structured core of Paf1C.
The purified Paf1C binds to Pol II in a substoichiometric manner in vitro, and another
transcription elongation factor TFIIS enhances this binding via its N-terminal domain.
Here, I report the cryo-electron microscopic structure of the ~1 megadalton yeast Pol II-
Paf1C-TFIIS EC. Protein crosslinking data, which together revealed that Paf1C extends over the
Pol II surface from lobe domain of Rpb2 to subunit Rpb3. The Paf1-Leo1 heterodimer and
Cdc73 contact Rpb2 and Rpb3, respectively, and from opposite ends of Paf1C, whereas Ctr9
bridges between them. My collaborators also show that Paf1C is globally required for mRNA
transcription in yeast. I used 4tU-Seq to monitor the newly synthesized RNA. Comparing RNA
synthesis in the wild-type strain and in strains lacking Paf1 or Rtf1, we found that Paf1C affects
Pol II transcription through the gene body. Moreover, in the absence of the subunit Rtf1, Paf1C
binding to RNA was dramatically reduced in vitro, indicating that Paf1C regulates transcription
elongation also through protein-RNA interactions. These results further indicate why Paf1C
binds only after disassembly of the transcription initiation complex; the initiation factor TFIIF
impairs Paf1C binding to Pol II.
These results provide the first three-dimensional framework for analyzing Paf1C function
in chromatin transcription and transcription-coupled events.
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1. Introduction
1.1 DNA-dependent RNA polymerases
All forms of life on earth use nucleic acids (NA) to store their genetic information. With the
exception of some viruses that utilize ribonucleic acids (RNA), the common biomolecule for
information storage is deoxyribonucleic acid (DNA). However, the information of DNA
sequences cannot be converted to proteins directly, but depends on interpretative RNA to
transport the information. The ‘Central Dogma of Molecular Biology’ defines this flow of
genetic information from DNA via messenger RNA (mRNA) to protein involving the processes
of transcription and translation. Transcription of genetic information from DNA to RNA is
catalyzed by DNA-dependent RNA polymerases (Pols) and can be found in all three kingdoms
of life. Bacteria and archaea have one Pol whereas eukaryotes use at least three different types of
Pols that synthesize distinct subsets of RNA molecules. Pol I is located in nucleoli and
sequentially transcribes 28S, 5.8S, and 18S ribosomal RNAs (rRNAs), ensuring synthesis of
equimolar amounts of these three rRNAs. Pol II and Pol III are located in the nucleoplasm. Pol II
transcribes all protein-coding messenger RNAs (mRNAs) as well as several small RNAs. Pol III
synthesizes all the transfer RNAs (tRNAs), 5S rRNA, U6 small nuclear RNAs (snRNA) and
other small cellular RNAs. In plants, two additional Pols called Pol IV and Pol V exist that
transcribe small interfering RNAs (siRNAs) required for heterochromatic silencing (Lahmy et al.,
2010; Matzke et al., 2009). Whereas the Pols mentioned above are multisubunit enzymes
(Table1), Pols in mitochondria and bacteriophages are single-subunit enzymes. Different from
mitochondria, chloroplasts transcription in higher plants is carried by two types of Pols. Plastid-
encoded Pol (PEP) is a bacteria-type multisubunit enzyme and transcribes photosynthesis genes
whereas nuclear-encoded Pol is a bacteriophage-type single-subunit enzyme and transcribes a
few house-keeping genes (Borner et al., 2015; Kanamaru & Tanaka, 2004).
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Table 1: Subunit composition of multisubunit RNA polymerases. Adapted from (Ream et al., 2009;
Vannini & Cramer, 2012; Weinzierl, 2013).
Pol I Pol II Pol III Pol IV Pol V Archaea Bacteria PEP
Core A190 Rpb1 C160 Nrpd1 Nrpe1 A’+A’’ β’ β’+ β’’
A135 Rpb2 C128 Nrpd2 Nrpd2 B’+B’’ β β
AC40 Rpb3 AC40 Nrpb3 Nrpb3/
Nrpe3b
D α α
AC19 Rpb11 AC19 Nrpd11 Nrpd11 L α α
A12.2 Rpb9 C11 Nrpb9b Nrpb9a/
Nrpb9b
- - -
Rpb5 Rpb5 Rpb5 Nrpb5 Nrpe5 H - -
Rpb6 Rpb6 Rpb6 Nrpb6 Nrpb6 K ω -
Rpb8 Rpb8 Rpb8 Nrpb8 Nrpb8 (G) - -
Rpb10 Rpb10 Rpb10 Nrpb10 Nrpb10 N - -
Rpb12 Rpb12 Rpb12 Nrpb12 Nrpb12 P - -
Stalk A14 Rpb4 C17 Nrpd4 Nrpd4 E - -
A43 Rpb7 C25 Nrpd7 Nrpe7 F - -
TFIIF-like A49 (Tfg1) C37 ? ? - - -
A34.5 (Tfg2) C53 ? ? - - -
Pol III specific - - C82 - - - - -
- - C34 - - - - -
- - C31 - - - - -
Subunits 14 12 17 12 12 12 (13) 5 5
Among multisubunit complexes, eukaryotic Pol I, Pol II, and Pol III contain 14, 12, and
17 subunits, respectively (Table 1) (Vannini & Cramer, 2012). Five of core subunits are shared
between Pol I and Pol II and two more between Pol I and Pol III (Table 1). The structure and
function of eukaryotic Pol I, Pol II, and Pol III has been well studied in the last decades (Cramer
et al., 2008). The first crystal structure of the 10-subunit Pol II core from Saccharomyces
cerevisiae (S. cerevisiae) was solved in 2000 (Cramer et al., 2000) and was later extended to a
complete 12 subunits with the peripheral Rpb4/7 stalk subcomplex (Armache et al., 2003;
Bushnell & Kornberg, 2003). The crystal structure of yeast Pol I was solved in two independent
studies (Engel et al., 2013; Fernandez-Tornero et al., 2013) and most recently, cryo-electron
3
microscopy (cryo-EM) structures of yeast Pol III were determined at medium-resolution
(Hoffmann et al., 2015). Single particle cryo-EM also allowed the first visualization of
mammalian Pol II at high resolution (Bernecky et al., 2016). Although eukaryotic Pol I, Pol II,
and Pol III have different composition, molecular weight and transcribe distinct subsets of genes,
the structural core and enzymatic mechanism is greatly conserved apparent from biochemical
studies and comparison of the structural information available (Cramer, 2002; Vannini & Cramer,
2012)
1.2 Regulation of RNA polymerase II
1.2.1 The RNA polymerase II transcription cycle
The transcription cycle of Pol II can be intuitively divided into five steps: pre-initiation, initiation,
elongation, termination and recycling (Hahn, 2004; Svejstrup, 2004) (Figure 1). During pre-
initiation Pol II assembles with numerous general transcription factors (GTFs) to form a giant
pre-initiation complex (PIC) localized at promoter sequences comprising a TATA box on closed,
double-stranded DNA. Once assembly of the PIC is complete, the closed, double-stranded DNA
is melted and the transcription bubble is formed. The single-stranded template DNA is inserted
into the Pol II active site where Pol II initiates transcription by synthesis of a nascent RNA (X.
Liu et al., 2013; Luse, 2013; Sainsbury et al., 2015). When the initially transcribed RNA reaches
at a length of  ~13 nucleotides, transcription switches to elongation by clearing the promoter and
exchanging initiation factors with elongation factors (Pal et al., 2005). During the elongation step,
the transcription bubble is retained (Martinez-Rucobo & Cramer, 2013). When the transcription
reaches the 3’ termini of genes, transcript cleavage and poly-adenylation (pA) occur (Proudfoot
et al., 2002; Svejstrup, 2004). Newly synthesized RNAs are released from Pol II at the pA site
while transcribing Pol II is terminated shortly after (Arndt & Reines, 2015; Schwalb et al., 2016).
Already co-transcriptionally, the pre-mRNA undergoes further processing (splicing) while
terminated Pol II can re-initiate for another transcription event.
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Figure 1: Pol II transcription cycle. Adapted from (Blombach et al., 2013). The five main steps are in
different colors. The transition from one step to the next is always accompanying the exchanges of
factors.
Each step of the Pol II transcription cycle is highly regulated by a large number of factors
with many types of interactions. Furthermore, specific secondary structures of nucleic acids
(Kassube et al., 2013; Lehmann et al., 2007) and post-translational modifications (PTMs) of the
Rpb1 carboxy-terminal domain (CTD) (Bowman & Kelly, 2014; Buratowski, 2009; Eick &
Geyer, 2013) play critical roles in transcription regulation.
1.2.2 General transcription factors in yeast
General transcription factors TFIIA, -B, -D, -E, -F, -H tightly regulate transcription initiation in
vivo (Table 2) (Sainsbury et al., 2015). The first step of pre-initiation complex assembly is the
binding of the saddle-shaped TFIID subunit TATA binding protein (TBP) to the TATA box
region of promoter DNA, which is located around 30-120 bp upstream of the transcription start
site (TSS). The minor groove of the TATA-box is bound by the concave surface of TBP, which
bends the DNA double helix by nearly 90° (J. L. Kim et al., 1993; Y. Kim et al., 1993). This
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allows the C-terminal core domain of transcription factor IIB (TFIIB) to bind to TATA-box and
surrounding upstream and downstream sequences in a cooperative manner (Kostrewa et al.,
2009; Littlefield et al., 1999; Sainsbury et al., 2013). The dispensable transcription factor TFIIA
is not required for basal transcription but can stabilize the TBP-DNA complex via binding to the
upstream region of the TATA box (Geiger et al., 1996). The N-terminal domain of TFIIB can
now recruit Pol II to the promoter. Binding of TFIIF to Pol II stabilizes the interaction with
TFIIB and prevents non-specific interactions with DNA (Cabart et al., 2011; Fishburn & Hahn,
2012). In later steps of transcription initiation, TFIIF stabilizes the transcription bubble and helps
the early RNA synthesis (Sainsbury et al., 2015). TFIIE is then recruited to the Pol II-DNA-
TBP-TFIIB-TFIIF complex, stabilizes it and promotes DNA melting. TFIIE also enhances the
affinity of TFIIH to the pre-initiation complex. Whereas TFIIE alone can already open certain
promoter DNA (Plaschka et al., 2016), the Ssl2 subunit of TFIIH unwinds the promoter DNA in
an ATP-dependent manner (Holstege et al., 1997; Holstege et al., 1996). Another important
function of TFIIH is phosphorylating the CTD via its Kin28 subunit. TBP, TFIIB, and TFIIF but
not TFIIE or TFIIH are minimally required for the transcription initiation in vitro (Fishburn &
Hahn, 2012).
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Table 2: General transcription factors in yeast. Adapted from (Sainsbury et  al., 2015; Sikorski &
Buratowski, 2009)
Protein complex Subunits Function
TFIIA 2 stabilizes the TBP-DNA complex; counteracts repressive effects of negative
co-factors
TFIIB 1 stabilizes the TBP-DNA complex; aids in the recruitment of Pol II and
TFIIF; directs accurate start site selection
TFIID 14 including TBP and TBP Associated Factors (TAFs); recognizes the
promoters; recruits Pol II
TFIIE 2 stabilizes the DNA opening; recruits TFIIH
TFIIF 3 stabilizes TFIIB;  directs accurate start site selection
TFIIH 10 promoters opening; DNA repair; phosphorylates CTD
TFIIS 1 stimulates the transcription elongation; induces mRNA cleavage and resume
transcription after arrest
1.2.3 The Carboxy-terminal domain (CTD)
The regulation of Pol II transcription by GTFs is only the initial point of transcriptional
regulation. Another important regulator for the transition between different stages is the
phosphorylation state of specific residues within the extended CTD of the largest Pol II subunit
Rpb1. The CTD is composed of dozens of tandem heptapeptide repeats with a consensus
sequence of tyrosine-serine-proline-threonine-serine-proline-serine (Y1-S2-P3-T4-S5-P6-S7).
Although very important in the Pol II system, Pol I and Pol III do not have a repetitive CTD in
their largest subunits Rpa1 and Rpc1, respectively. The number of hepta-repeats in the CTD of
Pol II may vary between different species. While yeast Pol II only has 26 repeats, mammalian
Pol II possesses a CTD with 52 repeats. However, the length of CTD seems not to be related to
the complexity of the organism (Eick & Geyer, 2013). Throughout the entire transcription cycle
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including pre-initiation, initiation, pausing, capping, elongation, selection of the RNA 3’
processing site and termination, the CTD is involved in regulatory events. Depending on the
functional context within the transcription process, all residues of the CTD repeats can be
dynamically modified and thereby regulate the recruitment of specific factors that recognize the
modifications. Tyrosine (Y1), threonine (T4), and serines (S2, S5, and S7) can be phosphorylated,
while the prolines (P3 and P7) can be isomerized. In addition to the phosphorylation, S5 and S7
can be O-glycosylated. Of these reversible modifications, S2 and S5 phosphorylation are the most
frequent and best-studied modifications. Briefly, phosphorylation on S5 was found in proximity
to promoter regions of genes showing its function in transcription initiation, whereas S2 was
found within the gene body according to productive elongation (Komarnitsky et al., 2000; Mayer
et al., 2010). The enzymes leading to the dynamic changes of those residues are kinases and
phosphatases, the so-called ‘writers’ and ‘erasers’, respectively. Factors that have a CTD
interaction domains (CID), which can recognize the modification patterns, are then ‘readers’ of
the established CTD code (Jeronimo et al., 2013). Furthermore, the CTD crosstalks with the
processing of epigenetic marks in chromatin by recruiting chromatin modifying proteins (Eick &
Geyer, 2013).
1.2.4 General transcription factor TFIIS
Different from the GTFs described above, which are mainly required for transcription initiation,
another GTF TFIIS is required during the transcription elongation (Table 2). TFIIS was first
discovered in 1972 (Natori et al., 1973) and is a single subunit protein, which consists of Domain
I (amino acid 1-77), Domain II (amino acid 148-238), Domain III (amino acid 265-309) and a
linker (amino acid 238-265) between Domain II and III (Kettenberger et al., 2003). Multiple
functions are described for TFIIS including binding to Pol II (Shimoaraiso et al., 1997) and
stimulation of the transcription elongation (Agarwal et al., 1991)
Most importantly, TFIIS triggers cleavage of nascent, backtracked mRNA when the
enzyme arrests during transcription (Kettenberger et al., 2003). Pol II arrests and backtracks
either because of nucleotide misincorperation or at sequences that are difficult to transcribe. In
such state, TFIIS is recruited, inserts its Domain III into the Pol II pore and cleaves the displaced
backtracked RNA. Cleavage activity of TFIIS is facilitated by two acidic residues D290 and
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E291 that can coordinate metal ion B in the Pol II active site and thereby stimulate transcript
cleavage (Cheung & Cramer, 2011; Kettenberger et al., 2003).
TFIIS is a specific factor for Pol II transcription, but the Pol I/III subunits A12.2 and C11
are functionally and structurally related to TFIIS (Arimbasseri et al., 2013; Chedin et al., 1998;
Engel et al., 2013; Hausner et al., 2000; Jennebach et al., 2012; Lisica et al., 2016).
1.2.5 Transcription elongation factors
Both structural and functional basis of transcription initiation have been well studied in the past
two decades. However, elongation is becoming increasingly considered as a key stage in
eukaryotic transcriptional regulation. The transition initiation to elongation occurs once the
nascent RNA transcript is extended beyond ~13 nucleotides (Sainsbury et al., 2015). This
transcript length is predicted to clash with the TFIIB ribbon domain at the RNA exit tunnel
ultimately inducing promoter clearance and the transition to elongation. As during initiation,
many factors are involved in regulating transcription elongation (Table 3). Before Pol II goes
into processive elongation, the early RNA synthesis steps are always accompanied by events as
promoter proximal pausing, backtracking, arrest, and reactivation, which are rate limiting steps
for transcription of a gene. Promoter proximal pausing happens shortly after initiation and was
found in metazoans. 5,6-dichloro-1-b -D-ribofuranosylbenzimidazole (DRB) sensitivity inducing
factor (DSIF) and negative elongation factor (NELF) were implicated in pausing (C. H. Wu et al.,
2003; Yamaguchi et al., 2013). Furthermore, Gdown1 is considered to stabilize poised Pol II in
the pausing state (Cheng et al., 2012). The paused transcription machinery can be released by the
positive transcription elongation factor b (P-TEFb), a subunit of the super elongation complex
(SEC) by phosphorylating NELF, DSIF and the CTD.
Another member of the SEC, the factor eleven-nineteen lysine-rich leukemia (ELL) also
increases the elongation rate. Other subunits of the SEC regulate elongation by direct interactions
or/and by serving as a docking platform for more factors (Luo et al., 2012).
Nucleosomes residing within gene bodies may impede Pol II during transcription
elongation and need to be overcome in order to maintain high elongation rates (~ 4 kb/min). The
tight complex of DNA wound around the core histone octamer (two molecules of each H2A,
H2B, H3, and H4) can be resolved by many different chromatin remodelers. Chd1, IWSI, Swi,
and Ino80, use the energy from ATP hydrolysis to change the nucleosome position, which
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increases accessibility for the transcription machinery. Histone chaperones as FACT and Spt6
directly bind to H2A-H2B and H3-H4, respectively, to disassemble histones from the
nucleosome particle and thereby enable Pol II to transcribe trough without displacing the entire
nucleosome (Belotserkovskaya & Reinberg, 2004; Belotserkovskaya et al., 2004). These histone
chaperones also regulate the enzymatic activity of histone tail modifying enzymes or serve as
interaction bridges between histones and PTM adding enzymes. The dynamically added and
removed post-translational modifications of histone tails like methylation, phosphorylation,
sumoylation, ubiquitination, acetylation, and glycosylation also influence transcription
elongation rate positively or negatively (Kwak & Lis, 2013; W. H. Liu & Churchill, 2012;
Petesch & Lis, 2012; Tessarz & Kouzarides, 2014). Elongation factors also can be recruited or
dissociated from elongating Pol II facilitating modified histone tails (Guccione et al., 2007;
Steward et al., 2006; J. Wu & Xu, 2012).
Table 3: A list of transcription elongation factors. Adapted from (Kwak & Lis, 2013).
Protein complex Subunits Function
NELF 4 stabilizes Pol II pausing
DSIF 2 stabilizes Pol II pausing; facilitates elongation
P-TEFb 2 phosphorylates NELF, DISF, and CTD of Pol II to release the elongation
from pause
ELL 1 increases the elongation rate
SEC 5-10 including P-TEFb and ELL; servers as a platform for other elongation
factors
CE 2 capping at RNA 5’ end
Gdown1 1 stabilizes paused Pol II
FACT 2 H2A-H2B chaperone
Spt6 1 H3-H4 chaperone
Chd1 1 chromatin remodeler
Paf1C 5 binds to Pol II; servers as a platform for other elongation factors; facilitates
the chromosomal transcription elongation, et.al. (see below)
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1.2.6 Structural studies on Pol II
The first crystal structure of the 10-subunit Pol II core was observed in 2000 and provided an
initial architecture of the enzyme (Cramer et al., 2000). Later, this was extended to a complete
12-subunit crystal structure, with the additional Rpb4-Rpb7 stalk sub-complex (Armache et al.,
2003; Bushnell & Kornberg, 2003). X-ray crystallographic structures of complete Pol II in
complex with factors or/and nucleic acids provide detailed insights in the mechanisms of RNA
synthesis by Pol II and how various factors assist and regulate this process. Structures of Pol II-
TFIIS in complex with a scaffold including a transcription bubble and a short RNA product show
how TFIIS binds to Pol II and facilitates RNA cleavage to release Pol II from arrested and
backtracked states (Cheung & Cramer, 2011; Kettenberger et al., 2003, 2004). The crystal
structure of Pol II-TFIIB with DNA and very short RNA transcripts, which mimic an initially
transcribing complex, revealed how TFIIB interacts with Pol II, positions DNA in the active site,
assists in transcription start site selection, helps DNA opening at the promoter of genes and
finally triggers promoter clearance. Another crystal structure of Pol II in complex with Bye1, a
homolog to TFIIS, shows that it binds to Pol II in a similar manner as TFIIS (Kinkelin et al.,
2013). However, different from TFIIS, Bye1 has a plant homeodomain (PHD), which can
recognize histone H3 containing trimethylated lysine 4 (H3K4) (Shi et  al., 2007), and suggests
Bye1 to be involved in transcribing packed chromatin in yeast (Kinkelin et al., 2013).
Recently, cryo-electron microscopy (cryo-EM) is becoming more and more powerful for
determining structures of biological macromolecules and in particular further elucidating the
mechanism of Pol II transcription at near-atomic resolution.
Medium resolution structures revealed the overall architectures of large transcription
related assemblies (He et al., 2013; Martinez-Rucobo et al., 2015; Plaschka et al., 2015;
Robinson et al., 2016). Bernecky et.al first determined the structure of a mammalian Pol II at 3.4
Å resolution using single particle cryo-EM, which ended the low-resolution electron microscopy
analysis of mammalian Pol II and its complexes (Bernecky et al., 2016). High resolution studies
of different yeast and human initiation complexes revealed conformational changes
accompanying the assembly of the initiation complex and suggested mechanisms for promoter
opening (He et al., 2016; Plaschka et al., 2016).
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1.3 Transcription factor Paf1 complex
The polymerase-associated factor 1 (Paf1) complex (Paf1C) is a general and conserved RNA
polymerase (Pol) II transcription elongation factor (Tomson & Arndt, 2013). Paf1C was first
identified through its co-purification with Pol II from yeast cells (Shi et al., 1997; Shi et al.,
1996; Wade et al., 1996). Yeast Paf1C comprises the subunits Paf1, Leo1, Ctr9, Cdc73, and Rtf1
(Koch et al., 1999; Krogan et al., 2002; Mueller & Jaehning, 2002; Squazzo et al., 2002). Paf1C
shows genetic interactions with the yeast transcription elongation factors Spt4-Spt5 and Spt16-
Pob3, the counterparts of human DSIF and FACT, respectively (Squazzo et al., 2002). Paf1C
also associates with transcribed regions in vivo (Pokholok et al., 2002), suggesting that it is a
transcription elongation factor. Paf1C subunits are required for efficient transcription in vivo
(Rondon et al., 2004).
1.3.1 Multiple functions of Paf1 complex in chromatin transcription
Paf1C has multiple roles in chromatin transcription. Yeast Paf1C functions in methylation of
histone H3 by Set1 and Dot1, thus linking transcription elongation to chromatin methylation
(Krogan et al., 2003). In yeast, Rtf1 binds the chromatin remodeler Chd1 (Simic et al., 2003) and
is required for ubiquitination of histone H2B (Ng et al., 2003; Wood et al., 2003; Xiao et al.,
2005) and histone methylation (Warner et al., 2007). Drosophila Rtf1 also functions in histone
methylation, gene expression, and Notch signaling (Tenney et al., 2006). Human Paf1C binds to
histone H3 tails with dimethylated histone H3 arginine17 (J. Wu & Xu, 2012).
Paf1C also has important functions that are not directly related to chromatin. Paf1C is
required for co-transcriptional RNA 3’-processing (Penheiter et al., 2005; Sheldon et al., 2005).
Human Cdc73 physically interacts with protein complexes required for 3’-processing
(Rozenblatt-Rosen et al., 2009). Paf1C also represses cryptic transcription (Y. Chu et al., 2007)
and is implicated in cellular differentiation (Kubota et al., 2014) and human cancer (Chaudhary
et al., 2007; Takahashi et al., 2011; Tan et al., 2010). Paf1C represses gene silencing by small
RNAs in S. pombe (Kowalik et al., 2015), and Leo1 is involved in heterochromatin spreading
(Verrier et al., 2015). Paf1C has recently been found to regulate Pol II phosphorylation,
promoter-proximal pausing, and release into gene bodies (F. X. Chen et  al., 2015; Yu et al.,
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2015). Paf1C is also involved in the resolution of transcription-replication conflicts (Poli et al.,
2016).
1.3.2 The recruitment of Paf1 complex during transcription
Paf1 is generally recruited to transcribed units, apparently entering the Pol II elongation complex
(EC) downstream of the transcription start site, and exiting at the polyadenylation (pA) site
(Mayer et al., 2010). There is evidence that Paf1C recruitment to Pol II requires direct contacts
with Pol II and additional contacts with Pol II-associated factors. Paf1C recruitment in vivo
requires the Bur1-Bur2 kinase (Laribee et al., 2005), and is aided by Spt4 (Qiu et al., 2006).
Paf1C and its Cdc73 subunit bind the phosphorylated CTD of Pol II and the phosphorylated C-
terminal repeat region (CTR) of Spt5, which is also a general elongation factor (Qiu et al., 2012).
A Plus3 domain in Rtf1 can bind the Spt5 CTR (Mayekar et al., 2013). Rtf1 is however not
stably associated with Paf1C in all species and is not required for Paf1C recruitment in human
cells, where it has non-overlapping functions (Cao et al., 2015). In fission yeast, Rtf1 also has
other functions (Mbogning et  al., 2013). The C-terminal GTPase-like domain of Cdc73 is
important for chromatin association of Paf1C (Amrich et al., 2012). Leo1 is also important for
Paf1C recruitment and binds RNA (Dermody & Buratowski, 2010).
1.3.3 Structural studies on Paf1 complex
Structural studies have revealed that Paf1C is a modular and flexible complex with several
structured regions. The crystal structure of a complex of regions in Paf1 and Leo1 revealed
antiparallel beta-sheets for heterodimerization (Figure 2) (X. Chu et al., 2013). This study also
showed that Ctr9 is a scaffold for Paf1C onto which the Paf1-Leo1 heterodimer and Cdc73
assemble. The structure of the GTPase-like domain in the C-terminal region of yeast Cdc73 was
also solved (Figure 2) (Amrich et al., 2012; H. Chen et al., 2012). In addition, structures were
reported for the Plus3 domain of human Rtf1 (de Jong et al., 2008; Wier et al., 2013), and for the
Plus3 domain in complex with a phosphorylated Spt5 CTR repeat (Figure 2) (Wier et al., 2013).
There is however no structural information on Ctr9, the largest Paf1C subunit.
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Figure 2: Crystal structures of Paf1C subunits. The ribbon models of solved domains within Paf1C (a,
GTPase-like C-terminal domain of Cdc73 from yeast; b, Paf1-Leo1 heterodimer from human; c, the Plus3
domain (red) in complex with phosphorylated Spt5 CTR peptide (green) in human). Adapted from PDB
entry: 3V46 (Amrich et al., 2012), 4M6T (X. Chu et al., 2013), and 4L1U (Wier et al., 2013),
respectively.
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1.4 Aims and scope
Although Paf1C has critical and ubiquitous roles in Pol II transcription, little is known about its
architecture, how it associates with Pol II and its way of function as an elongation factor. The
primary goal of this thesis was to determine the structure of the entire Paf1C by crystallographic
methods and further investigate Paf1C function with biochemical assays. The entire complex
could be recombinantly expressed in Escherichia coli (E. coli) and reconstituted in vitro with
high quality and excellent yields. However, crystallization remained unsuccessful. Limited
proteolysis indicated a high degree of flexibility for the entire complex leading to the design of
truncated constructs based on results from limited proteolysis, Edman sequencing and cross-
linking coupled with mass spectrometry. Crystals from a Paf1C variation could be obtained by in
situ proteolysis with chymotrypsin that diffracted only to 7 Å.
Then I aimed to determine the Paf1C structure together with Pol II. Simultaneously, a
complex of Paf1C with Pol II and TFIIS was assembled because TFIIS was shown to enhance
Pol II-Paf1C interactions. The architecture of the Pol II-Paf1C-TFIIS transcription elongation
complex was then studied by cryo-EM and crosslinking coupled to mass spectrometry. The
determined architecture reveals a trilobal architecture of Paf1C and the location of Paf1C on
elongating Pol II. Existing crystal structures and crosslinking coupled to mass spectrometry data
allowed assignment of several Paf1C subunits to the EM density. Comparing this structure to a
Pol II-TFIIF initiation complex structure, it was apparent, that part of Paf1C occupies a similar
binding site as the TFIIF dimerization domain. Complementary analytical sucrose gradient
ultracentrifugation assays proved competitive binding of the two.
I also aimed to know if Paf1C infects the global transcription in yeast. Our 4tU-Seq
reveals subunits Paf1 and Rtf1 are key co-transcriptional factors during Pol II transcription.
Finally, the interaction of Paf1C to RNA in the presence or absence of Rtf1 was studied,
showing that removal of Rtf1 decreases affinity of Paf1C for RNA. It suggests Paf1C regulates
the transcription not only rely on the protein-protein interaction, but also on protein-RNA. All
together, this work provides a basis for mechanistic investigation of a central player in
transcription elongation.
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2. Materials and Methods
2.1 Materials
2.1.1 Bacterial strains
Table 4: E. coli strains used in this study.
Strain Description Source
XL1-Blue endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44
F'[ ::Tn10 proAB+ lacIq Δ(lacZ)M15] hsdR17(rK-
mK+)
nalidixic acid resistant, tetracycline resistant (carried
on the F plasmid)
Stratagene
BL21-CodonPlus(DE3)-RIL E. coli B F– ompT hsdS(rB– mB–) dcm+ Tetr gal
λ(DE3) endA Hte [argU ileY leuW Camr]
for high-level protein expression and easy induction in
T7 expression systems
Stratagene
2.1.2 Yeast strains
Table 5: Yeast strains used in this study.
Strain Description Source
BJ5464 Rpb3 His-Bio BJ5464 Rpb3 His-Bio tag introduced at 5’ end of
Rpb3 gene, use of URA3 selection marker
for endogenous Pol II purification
(Kireeva et al.,
2003)
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0
for 4tU-Seq
Euroscarf
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Strain Description Source
∆Paf1 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 paf1::kanMX
for 4tU-Seq
Euroscarf
∆Rtf1 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 rtf1::kanMX
for 4tU-Seq
Euroscarf
2.1.3 Plasmids
Table 6: Plasmids used in this study. The genes chemically synthesized by GeneArtTM (Thermo Fisher
Scientific) are labeled in up case.
Vector Insert Type Tag Res. Source
YXU001 Cdc73 pET21b C-6xHis Amp this work
YXU002 Leo1 pET21b C-6xHis Amp this work
YXU003 Paf1 pET21b C-6xHis Amp this work
YXU004 Ctr9 pET21b C-6xHis Amp this work
YXU005 Rtf1 pET21b C-6xHis Amp this work
YXU006 Cdc73 (184-393) pET21b C-6xHis Amp this work
YXU007 Cdc73 (201-393) pET21b C-6xHis Amp this work
YXU008 Cdc73 (235-393) pET21b C-6xHis Amp this work
YXU009 Yaf9 (YEATS, 8-176) pGEX4T-1 N-GST-
Thrombin
Amp this work
YXU010 Yaf9 (YEATS, 8-176) pETDuet1 N-6xHis Amp this work
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Vector Insert Type Tag Res. Source
YXU011 Paf1-Yaf9 pETDuet1 Paf1, N-
6xHis
Amp this work
YXU012 Paf1-Yaf9 (YEATS,8-176) pETDuet1 Paf1, N-6x
His
Amp this work
YXU013 Ctr9-Cdc73 pETDuet1 Ctr9, N-
6xHis
Amp this work
YXU014 Paf1-Leo1 pETDuet1 Paf1, N-6x
His
Amp this work
YXU015 Leo1- Paf1 pETDuet1 Leo1, N-6x
His
Amp this work
YXU016 Ctr9-Leo1 pETDuet1 Ctr9, N-6x
His
Amp this work
YXU017 Cdc73-Paf1 pETDuet1 Cdc73, N-
6x His
Amp this work
YXU018 Paf1-Cdc73 pETDuet1 Paf1, N-6x
His
Amp this work
YXU019 Cdc73 pETDuet1 Amp this work
YXU020 Cdc73 (229-393) pGEX4T-1 N-GST-
Thrombin
Amp this work
YXU021 Ctr9 (56-251) pETDuet1 N-6xHis Amp this work
YXU022 Ctr9 (56-371) pETDuet1 N-6xHis Amp this work
YXU023 Ctr9 (56-462) pETDuet1 N-6xHis Amp this work
YXU024 Ctr9 (56-534) pETDuet1 N-6xHis Amp this work
YXU025 Ctr9 (56-811) pETDuet1 N-6xHis Amp this work
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Vector Insert Type Tag Res. Source
YXU026 Ctr9 (56-967) pETDuet1 N-6xHis Amp this work
YXU027 Ctr9 (56-1077) pETDuet1 N-6xHis Amp this work
YXU028 Cdc73 pGEX4T-1 N-GST-
Thrombin
Amp this work
YXU029 Cdc73 (1-228) pGEX4T-1 N-GST-
Thrombin
Amp this work
YXU030 Ctr9 (461-967) pETDuet1 N-6xHis Amp this work
YXU031 Ctr9 (461-1077) pETDuet1 N-6xHis Amp this work
YXU032 Ctr9 (731-967) pETDuet1 N-6xHis Amp this work
YXU033 Ctr9 (731-1077) pETDuet1 N-6xHis Amp this work
YXU034 Ctr9 (811-967) pETDuet1 N-6xHis Amp this work
YXU035 Ctr9 (811-1077) pETDuet1 N-6xHis Amp this work
YXU036 Ctr9 (811-967)-Cdc73 pETDuet1 N-6xHis Amp this work
YXU037 Rtf1-Cdc73 pRSFDuet1 Rtf1, N-
6xHis
Kan this work
YXU038 Leo1 pCDFDuet1 Sm this work
YXU039 Cdc73 pET24b Kan this work
YXU040 Ctr9 (888-1077) pET21b C-6xHis Amp this work
YXU041 Ctr9 (888-1077) pET24b Kan this work
YXU042 Paf1 (150-445) pET21b C-6xHis Amp this work
YXU043 Paf1 (150-445) pET24b Kan this work
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Vector Insert Type Tag Res. Source
YXU044 Paf1 (150-445) pET21b Amp this work
YXU045 Paf1 (230-445) pET21b C-6xHis Amp this work
YXU046 Paf1 pET24b Kan this work
YXU047 Ctr9 pET24b C-6xHis Kan this work
YXU048 Paf1 (277-445) pET21b C-6xHis Amp this work
YXU049 Rtf1 (246-558) pET21b C-6xHis Amp this work
YXU050 Paf1 (277-445) pET24b Kan this work
YXU051 Rtf1-Cdc73 pET21b Amp this work
YXU052 Ctr(801-1011) pET24b Kan this work
YXU053 Paf1 (150-445)-Cdc73 pET24b Kan this work
YXU054 Paf1 (150-445)-
Yaf9(YEATS, 8-176)
pET24b Kan this work
YXU055 Paf1 (178-445) pET21b C-6xHis Amp this work
YXU056 Paf1 (194-445) pET21b C-6xHis Amp this work
YXU057 Paf1 (207-445) pET21b C-6xHis Amp this work
YXU058 Paf1 (241-445) pET21b C-6xHis Amp this work
YXU059 Paf1 (264-445) pET21b C-6xHis Amp this work
YXU060 Leo1 (49-464) pCDFDuet1 Sm this work
YXU061 Leo1 (107-464) pCDFDuet1 Sm this work
YXU062 Leo1 (165-464) pCDFDuet1 Sm this work
YXU063 Leo1 (213-464) pCDFDuet1 Sm this work
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Vector Insert Type Tag Res. Source
YXU064 Paf1 (178-445) pET24b C-6xHis Kan this work
YXU065 Paf1 (1-276) pET21b C-6xHis Amp this work
YXU066 Paf1 (90-276) pET21b C-6xHis Amp this work
YXU067 Paf1 (90-445) pET21b C-6xHis Amp this work
YXU068 Leo1 (107-310) pCDFDuet1 Sm this work
YXU069 Leo1 (1-437) pCDFDuet1 Sm this work
YXU070 Leo1 (107-391) pCDFDuet1 Sm this work
YXU071 Leo1 (107-437) pCDFDuet1 Sm this work
YXU072 Rtf1 (397-558) pET24b C-6xHis Kan this work
YXU073 PAF1 pET21b C-6xHis Amp this work
YXU074 Leo1-PAF1 pCDFDuet1 Sm this work
YXU075 PAF1 (150-445) pET21b C-6xHis Amp this work
YXU076 LEO1-PAF1 pCDFDuet1 Sm this work
YXU077 Ctr9 (1-810) pET24b C-His Kan this work
YXU078 Ctr9 (1-867) pET24b C-His Kan this work
YXU079 Ctr9 (1-887) pET24b C-His Kan this work
YXU080 Ctr9 (1-913) pET24b C-His Kan this work
YXU081 Ctr9 (1-966) pET24b C-His Kan this work
YXU082 LEO1 (93-464)-PAF1 pCDFDuet1 Sm this work
YXU083 Rtf1 (397-558)-Cdc73 pET21b Amp this work
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Vector Insert Type Tag Res. Source
YXU084 Rtf1 (442-558)-Cdc73 pET21b Amp this work
YXU085 LEO1 (118-376)-PAF1 (1-
360)
pCDFDuet1 Sm this work
YXU086 Rtf1-Cdc73 pGEX4T-1 Rtf1, N-
GST-
Thrombin
Amp this work
YXU087 SPT5 pET21b Amp this work
YXU088 Spt4 pOPINK N-6xHis-
GST-3C
Kan this work
2097 Spt5 (CTR) pET28a N-6xHis-
GST
Kan Amelie
Schreieck
224 TFIIS pET28a N-6xHis Kan Hubert
Kettenberger
225 TFIIS (131-309) pET28a N-6xHis Kan Hubert
Kettenberger
SS191 TFIIS (D290A/E291A)
(TFIIS (DE-AA))
pET28a N-6xHis-
GST-3C
Kan Sarah Sainsbury
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2.1.4 Synthetic Genes and oligonucleotides
Table 7: Synthetic genes used in this study.
Name Organism Company Comment
PAF1 S. cerevisiae GeneArt Codon optimized for E. coli
LEO1 S. cerevisiae GeneArt Codon optimized for E. coli
SPT5 S. cerevisiae GeneArt Codon optimized for E. coli
Table 8: Synthetic oligonucleotides in this study.
Name Sequence (5’-3’) Usage
Template DNA AAGCTCAAGTACTTAAGCCTGGTCATTACTAGT
ACTGCC
Pol II elongation complex
Non-template DNA GGCAGTACTAGTAAACTAGTATTGAAAGTACTT
GAGCTT
Pol II elongation complex
RNA-20 UAUAUGCAUAAAGACCAGGC Pol II elongation complex
RNA-50 GAACGAGAUCAUAACAUUUGAACAAGAAUAU
AUAUACAUAAA
Pol II elongation complex
Coding RNA-33 FAM-
AAUAUUCAAGACGAUUUAGACGAUAAUAUCA
UA
Fluorescence anisotropy
assays
Random RNA-33 FAM-
AAUAUUCAAGCAGUAUUAGCAGUAAAUAUCA
UA
Fluorescence anisotropy
assays
FAM-RNA-20 FAM-UAUAUGCAUAAAGACCAGGC Transcription elongation
assay
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Name Sequence (5’-3’) Usage
TA-1-tempalte DNA ACAAATTACTGGGAAGTCGACTATGCAATACA
GGCATCATTTGATCAAGCTCAAGTACTTAAGCC
TGGTCATTACTAGTACTGCC
Transcription elongation
assay
TA-1-nontemplate DNA GGCAGTACTAGTAATGACCAGGCTTAAGTACTT
GAGCTTGATCAAATGATGCCTGTATTGCATAGT
CGACTTCCCAGTAATTTGT
Transcription elongation
assay
FAM-GK-RNA-20 FAM-UAUACAUAAUGGAGUAGGGU Transcription elongation
assay
GK-TA-pML5 template
DNA
AGGAAGCTAAAATGGAGAAAAAAATCACTGGA
TATACCACCGTTGATATATTACCCTACTCCATA
ACTTCAACAACC
Transcription elongation
assay
GK-TA-pML5
nontemplate DNA
GGTTGTTGAAGTTATGGAGTAGGGTAATATATC
AACGGTGGTATATCCAGTGATTTTTTTCTCCATT
TTAGCTTCCT
Transcription elongation
assay
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2.1.5 Growth medium and additives
Table 9: Growth medium for E. coli and S. cerevisiae.
Medium Application Description
Lysogeny broth (LB) E. coli 1 % (w/v) tryptone, 0.5 % (w/v)
yeast extract, 0.5 % (w/v) NaCl
LB plates E. coli 1 % (w/v) tryptone, 0.5 % (w/v)
yeast extract, 0.5 % (w/v) NaCl,
1.5% (w/v) agar
Yeast Extract-Peptone-Dextrose
Broth (YPD)
S. cerevisiae 2% (w/v) peptone, 2% (w/v)
glucose, 1% (w/v) yeast extract
YPD plates S. cerevisiae 2% (w/v) peptone, 2% (w/v)
glucose, 1% (w/v) yeast extract,
1.5% (w/v) agar
Table 10: Medium additives for E. coli and S. cerevisiae.
Additive Stock solution Applied concentration Application
Ampicillin 100 (w/v) mg/ml in H2O 0.1 mg/L Antibiotic
Kanamycin 50(w/v) mg/ml in H2O 0.05 mg/L Antibiotic
Chloramphenicol 30 (w/v) mg/mL in
Ethanol
0.03 mg/L Antibiotic
Streptomycin 50(w/v) mg/ml in H2O 0.05 mg/L Antibiotic
IPTG 1 M in H2O 0.5 mM Protein expression
induction
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2.1.6 Buffers and solutions
Table 11: General buffers, dyes and solutions.
Name Description Application
1x TE 10 mM Tris-HCl pH 8.0, 1 mM
EDTA
Various
10x DNA loading dye Thermo Fisher Scientific Agarose gel electrophoresis
GeneRuler 1 kb DNA Ladder Thermo Fisher Scientific Agarose gel electrophoresis
10x TAE 50 mM EDTA pH 8.0, 2.5 M Tris-
acetate
Agarose gel electrophoresis
SYBR Safe Thermo Fisher Scientific DNA gel stain
Electrophoresis buffer 20x MOPS NuPAGE buffer (Life
Technologies/Thermo Fisher
Scientific)
SDS-PAGE
5X SDS loading dye 10% (w/v) SDS, 10 mM DTT, 20%
(v/v) glycerol, 0.2 M Tris-HCl pH
6.8, 0.05% (w/v) bromophenol blue
SDS-PAGE
Instantblue Expedeon SDS-PAGE
SDS-PAGE Coomassie staining
solution
50% (v/v) ethanol, 7% (v/v) acetic
acid, 0.125% (w/v) Coomassie
Brilliant Blue R-250
SDS-PAGE
Destain solution 5% (v/v) ethanol, 7.5% (v/v) acetic
acid
SDS-PAGE
Broad-Range SDS-PAGE Standards Bio-Rad Laboratories SDS-PAGE
Prestained Protein Ladder Thermo Fisher Scientific SDS-PAGE
Silver nitrate solution 0.1% (w/v) silver nitrate, 0.01%
(v/v) formalin (37% formaldehyde)
Silver staining
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Name Description Application
Developing solution 3% (w/v) sodium carbonate, 0.05%
(v/v) formalin (37% formaldehyde)
Silver staining
Transfer buffer (commercial) NuPAGE TransferBuffer (Life
Technologies/Thermo Fisher
Scientific)
Western blot
Transfer buffer 25mM Tris, 192mM glycine, 20%
ethanol
Western blot
100x Protease inhibitor (PI) 0.028 mg/mL Leupeptin, 0.137
mg/mL Pepstatin A, 0.017 mg/mL
PMSF, 0.33 mg/mL Benzamidine in
ethanol
Protein purification
1X PBS 137mMNaCl, 2.7mMKCl,
10mMNa2HPO4, 1.76mM KH2PO4
pH 7.4
Western blot
Table 12: Buffers used for preparation of competent E. coli cells.
Name Description
TFB-I 30 mM KOAc, 50 mM MnCl2, 100 mM RbCl, 10 mM
CaCl2, 15 % (v/v) glycerol
pH set with HOAc at 5.8 at 4 °C
TFB-II 10 mM MOPS, pH 7.0 at 4 °C, 75 mM CaCl2, 10 mM
RbCl, 15 % (v/v) glycerol
27
Table 13: Enzymes, buffers, and components used for cloning.
Name Source
2x Phusion High-Fidelity PCR Master Mix New England Biolabs
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich
Restriction enzymes New England Biolabs, Fermentas
FastaAP Fermentas
DpnI New England Biolabs
QIAquick PCR purification kit Qiagen
QIAquick gel extraction kit Qiagen
T4 DNA Ligase New England Biolabs
10x T4 DNA ligase reaction buffer New England Biolabs
Quick T4 DNA Ligase New England Biolabs
2x Quick ligation buffer New England Biolabs
QIAprep spin miniprep kit Qiagen
Table 14: Buffers used for Paf1C purification, crosslinking and pull-down.
Name Description Application
Buffer A 50 mM Tris pH 8.7, 600 mM
potassium acetate (KOAc), 2 mM
dithiothreitol (DTT), 2 mM MgCl2,
10 mM imidazole, 10 µM ZnCl2
Purification
Buffer B 50 mM Tris pH 8.7, 70 mM KOAc,
2 mM MgCl2, 2 mM DTT, 10 µM
ZnCl2
Purification
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Name Description Application
Buffer C 10 mM Tris pH 8.5, 200 mM NaCl,
2 mM MgCl2, 2 mM DTT, 10 µM
ZnCl2
Purification
Buffer D 10 mM Hepes pH 7.5, 100 mM
NaCl, 2 mM MgCl2, 2 mM DTT, 10
µM ZnCl2
Crosslinking and Pol II-Paf1C-TFIIS
elongation complex preparation
Buffer P 50 mM Hepes pH 7.5, 0.1% NP-40,
150 mM KOAc, 2 mM DTT
Pull-down assays
Table 15: Buffers used for sucrose gradient ultracentrifugation and fixation.
Name Description Application
Light solution 10 mM Hepes pH 7.5, 100 mM
NaCl, 2 mM DTT, 2 mM MgCl2, 10
µM ZnCl2, 10% (v/v) sucrose
Gradient fixation (with heavy
solution 1), and gradient
ultracentrifugation (with heave
solution 2)
Heavy solution 1 10 mM Hepes pH 7.5, 100 mM
NaCl, 2 mM DTT, 2 mM MgCl2, 10
µM ZnCl2, 30% (v/v) sucrose,
0.075% (v/v) glutaraldehyde
Gradient fixation
Heavy solution 2 10 mM Hepes pH 7.5, 100 mM
NaCl, 2 mM DTT, 2 mM MgCl2, 10
µM ZnCl2, 30% (v/v) sucrose
Gradient ultracentrifugation
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Table 16: Buffers used for fluorescence anisotropy assays.
Name Description
Buffer F 200 mM NaCl, 10 mM Tris pH 8.0, 1 mM TCEP, 2.4 µl,
and 2 mM MgCl2
Buffer G 10 mM Tris pH 8.0, 1 mM TCEP, 2 mM MgCl2, 8%
glycerol, 0.02 mg/ml BSA, 10 µg/ml yeast tRNA
Table 17: Buffers used for transcription elongation assays.
Name Description
10x TBE Sigma-Aldrich
1x Transcription buffer (TB) 100 mM NaCl, 30 mM Hepes pH 7.5, 3 mM MgCl2, 2
mM DTT, 4% (v/v) glycerol
2x Stop buffer 1x TBE buffer, 50 mM EDTA pH 8.0, 6.5 M urea, 0.33
µg/µL proteinase K
20% TBE urea gel 8M urea, 1x TBE, 20% 19:1 acrylamide 40% solution,
0.5% (v/v) APS stock (10% (w/v)), 0.1% TEMED
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2.2 Methods
2.2.1 Molecular cloning
Cloning strategy
The gene sequences encoding for Ctr9, Rtf1, Paf1C, Leo1, and Cdc73 were amplified from
Saccharomyces cerevisiae (S. cerevisiae) genomic DNA by polymerase chain reaction (PCR). In
addition, open reading frames of Paf1 and Leo1 were chemically synthesized by GeneArtTM
(Thermo Fisher Scientific) to optimize codon usage for more efficient expression in bacteria
(Table 7). Each coding region was preceded by a ribosome binding sequence (RBS). Multiple
proteins were cloned either in a vector containing two multiple cloning sites (MCS) or in in-
house modified vectors. To increase the expression yield, different tags, C-terminal or N-
terminal hexa-histidine tag, or untagged together with the sequential coding genes were as
indicated in the plasmids list (Table 6). Plasmids with different antibiotic resistances were used
for co-expression.
Polymerase Chain Reaction (PCR)
Oligonucleotide PCR primers were designed generally with a length of ~39 nucleotides
containing ~21 nucleotides complementary to the target sequences with a GC content of 40-60%,
and also with two restriction enzymes sites simultaneously. There were minor changes for
amplifying some difficult targets. PCR was carried out by using 2x Phusion High Fidelity PCR
Master Mix (NEB), both forward and reverse primers, and DNA templates. The reactions were
generally performed in a Biometra T3000 Thermocycler with ~30 thermocycles. The annealing
temperature and extension time was dependent on the GC content of the complementary
nucleotides and the length of the coding genes. PCR products were visualized by agarose gel
electrophoresis with Sybr Safe stain (Thermo Fisher Scientific). 1 µl of DpnI (NEB) was added
to the PCR products and incubated at 37 °C for 1 hour to digest the template plasmids. The PCR
products were purified using QIAquick PCR purification kit (Qiagen, Table 11).
Restriction digest and dephosphorylation
Purified PCR products and vectors were double digested using appropriate restriction enzymes
and reaction buffer (NEB) at 37 °C for 2 hours. Linearized vectors were further
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dephosphorylated with FastaAP (NEB). Dephosphorylated vectors and cleaved coding gene
fragments were purified using agarose gel electrophoresis and subsequently the QIAquick Gel
Extraction Kit (Qiagen). 30 ng of vector and 4-fold molar excess of target gene were ligated
using the Quick ligation kit (NEB) in a 20-µl reaction volume at room temperature for 5 min as
recommended by the manufacturer.
Chemically competent cells preparation
Two strains of chemically competent E. coli cells were used in this study for transformation
(Table 4). Ligation products were transformed in to XL 1-Blue cells. This strain of E. coli cells
was also used for plasmids amplification. The other strain, BL21 CodonPlus(DE3)RIL cells were
used for protein over-expression.
To prepare chemically competent cells, 5 ml LB medium culture containing appropriate
antibiotics and E. coli cells were grown at 37 °C at 140 rpm overnight. 500 ml LB medium with
appropriate antibiotics (Table 10) was inoculated by the overnight culture in a ratio of 1:100 and
cells were grown at 37 °C with 140 rpm shaking for ~3 hours to an OD600nm of ~0.3. The culture
was put on ice for 10 min followed by centrifugation at 4,000 x g at 4 °C for 5 min to harvest the
cells. From this step on, the cells were kept on ice. After resuspending in 100 ml pre-chilled
Transformation buffer 1 (TFB-1) (Table 12), the cells were incubated on ice for 5 min again
subsequently cell were harvested by centrifugation at 4,000 x g at 4 °C for 5 min. The
supernatant was discarded, and the pellet was resuspended in 10 ml Transformation buffer 2
(TFB-2) (Table 12). After another incubation on ice for 15 min, 50 µl aliquots were flash frozen
in liquid nitrogen and stored at -80 °C.
Transformation, plasmid verification and sequencing
The competent cells were thawed on ice and 10 µl out of 20 µl ligation product or 50 ng pure
plasmid was added and incubated on ice for 20 min. The competent cells were heat shocked at 42
°C for 1 minute followed by an incubation on ice for 2 min. 450 µl LB medium was added and
cells were recovered at 37 °C for 45 min with 900 rpm sharking in a thermomixer (eppendorf).
Cells were then plated on LB agar plates containing the appropriate antibiotic, and incubated at
37 °C overnight. 5 ml LB medium containing the appropriate antibiotic was inoculated with a
single colony and incubated at 37 °C with 150 rpm shaking overnight. 0.2 µl of the culture was
32
used as template for colony PCR. After analyzing the PCR products by agarose gel
electrophoresis, plasmids DNA of positive colonies was extracted using the Miniprep
purification kit (Qiagen). Plasmid sequence was further confirmed by sequencing (GATC). For
protein co-expression, two or three plasmids were co-transformed into the same competent cells
at the same time and plated on LB agar plates containing multiple antibiotics.
Determination of nucleic acid concentration
All the nucleic acid concentrations were determined using a NanoDrop-2000 spectrophotometer
(Thermo Fisher Scientific) by measuring the absorption at 260 nm.
2.2.2 General protein methods
Protein expression and purification
All the proteins except yeast endogenous RNA polymerase II used in this study were expressed
in E. coli. Protein purification usually includes affinity purification, ion exchange and size
exclusion chromatography (see 2.2.3 Specific methods).
Protein concentrating, determination of concentration, and storage
Proteins were concentrated using AMICON Ultra centrifugal concentrators (Millipore) or
Vivaspin concentrators (GE) with a proper molecular weight cutoff. All the protein
concentrations were determined using a NanoDrop-2000 spectrophotometer (Thermo Fisher
Scientific) by measuring the absorption at 280 nm. The extinction coefficients were calculated
using ProtParam (http://web.expasy.org/protparam/). The aliquots of purified proteins were
flash-frozen in liquid nitrogen and stored at -80 °C.
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)
Protein samples were mixed with 5 x SDS-PAGE loading dye (Table 11) followed by an
electrophoretic separation using precast NuPAGE Novex 4-12% Bis-Tris gels (Invitrogen).
Protein marker (PageRuler Prestained Protein Ladder, Thermo Fisher Scientific) was loaded as a
size control. Gels were run in 1 x MOPS running buffer (Invitrogen) at 200 V for 45-90 min and
stained with InstantBlue (Expedeon) before imaging. In case of low protein concentration,
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trichloroacetic acid (TCA) precipitation was used before loading samples on the gels, or silver
staining was used to detect proteins after electrophoretic separation (see below).
Trichloroacetic acid (TCA) protein precipitation
TCA was added to a final concentration of 10% to the protein sample and incubated at -20 °C for
10 min. The solution was centrifuged for 10 min at 14,000 rpm at 4 °C and the supernatant was
carefully removed. The pellet was washed with 1 ml pre-chilled (-20 °C) acetone. Centrifugation
was carried out as before and the supernatant was carefully removed before incubating for 5 min
at 95 °C to evaporate the residual acetone. The pellet was resuspended in 10-15 µl water and 5 µl
5 x SDS loading dye. If the sample turned yellow, indicating a pH change, Tris pH 8 was added
until the sample turned blue.
Silver staining
The acrylamide gel was first rinsed twice in water to remove the MOPS buffer, and then soaked
in 40 ml 50% (v/v) ethanol for 20 min and then 40 ml 5% (v/v) ethanol for 20 min, and then in
40 ml water containing 35 µM DTT for 5 min followed by soaking the gel in 40 ml silver nitrate
solution (Table 11) for 10 min. The gel was rinsed twice with 40 ml water each time and 25 ml
ice-chilled developing solution (Table 11) before soaked in 50 ml ice-chilled developing solution
to the desired darkness of the protein bands. Solid citric acid monohydrate was added to
neutralize the pH and stop the reaction. The gel was transferred to water and imaged.
Protein identification
Mass spectrometry was carried out for protein identification by the protein analysis core facility
of Adolf-Butenandt-Institute at LMU, Munich or Thomas Fröhlich at the Genzentrum, LMU,
Munich or by Monika Raabe from Urlaub laboratory at the MPIbpc, Göttingen.
Western blot
Protein samples were applied to SDS-PAGE and transferred to polyvinylidene difluoride
(PVDF) membranes (GE Healthcare) using the Trans-Blot Turbo Blotting system (Bio-Rad). The
transfer was done in ice-cold 1x transfer buffer (Table 11) at 150 V for 90 min on ice. The
membrane was either stained with Ponceau S for Edman sequencing (see 2.2.3 Specific methods)
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or for immunostaining. Immunostaining against His antibody was mainly used in this study. The
membrane was first blocked with 2 % milk for 30 min at room temperature in 1x PBS (Table 11)
containing 0.02% Tween 20 (PBS-T). Then the membrane was incubated with the primary
antibody in 2% milk in PBS-T at 4 °C overnight. The membrane was washed three times with 2%
milk in PBS-T for 5 min for each wash before incubating with the secondary antibody for 60 min
at room temperature. The membrane was washed as described before developing using the Super
SignalWest Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and imaged with an
Advanced Fluorescence Imager (Intas).
2.2.3 Specific methods
Pol II, TFIIS, and TFIIF purification
Endogenous S. cerevisiae Pol II, recombinant TFIIF, and recombinant TFIIS and its variants
were purified as described (Kettenberger et al., 2003, 2004; Plaschka et al., 2016; Sydow et al.,
2009).
Scaffold preparation
To anneal DNA-RNA scaffolds for elongation complex preparation and in vitro transcription
elongation assays, synthetic oligonucleotides were dissolved in TE (Table 11) to a final
concentration of 400 µM. Equimolar amounts of template DNA and RNA were mixed in a PCR
tube. The mixed DNA-RNA scaffolds were incubated at 95 °C for 5 min and then annealed by
reducing the temperature from 95 °C to 20 °C in 1 °C/min steps using the Thermocyler
(Biometra). The annealed scaffolds were stored at -80 °C.
Paf1C expression and purification
The gene sequences encoding for Ctr9, Rtf1, Cdc73 were amplified from the S. cerevisiae
genomic DNA by PCR. Open reading frames of Paf1 and Leo1 were chemically synthesized by
GeneArtTM (Thermo Fisher Scientific) to optimize codon usage for more efficient bacterial
expression. Full-length Ctr9 was cloned into pET24b (Novagen) resulting in a non-cleavable
hexa-histidine tag fused to the Ctr9 carboxyl-terminus. The PCR products of full-length Rtf1 or
Cdc73 were cloned into an in-house modified version of the pET21b vector (Novagen).
Ribosome binding sequence (RBS)-Cdc73, which contains an RBS on the amino-terminus of
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Cdc73 was inserted sequentially after Rtf1. Additionally, Cdc73 was cloned into multiple
cloning sites 2 (MCS2) of pETDuet-1 (Novagen) for the co-expression of a four-subunit Paf1
complex   lacking Rtf1 (Paf1C-∆Rtf1). Leo1 and Paf1 were PCR-amplified and cloned into two
multiple cloning sites of pCDFDuet-1 vector (Novagen) separately and sequentially. The five-
subunit Paf1C and its variants were heterologously co-expressed in E. coli BL21 CodonPlus
(DE3)RIL cells (Stratagene). Cultures of bacteria transformed with pET24b-Ctr9 and
pCDFDuet-1-Leo1-Paf1 were grown in LB medium at 37 ºC to an OD600nm of ~0.8. The
temperature was reduced to 18 °C, and protein over-expression was induced by addition of 1
mM isopropyl-b-D-thiogalactoside (IPTG) and with continued growth at 18 °C overnight. The
same strategy was used for the co-expression of Rtf1 and Cdc73.
Cells were harvested and co-lysed by sonication in buffer A (Table 14) containing a
1:100 dilution of protease inhibitor cocktail (1 mM leupeptin, 2 mM pepstatin A, 100 mM
phenylmethylsulfonyl fluoride, 280 mM benzamidine), 1,000 units benzonase, and 0.4 µg/mL
DNaseI. The extract was cleared by centrifugation (20,000 x g, 30 min) and the supernatant was
loaded onto a 2-ml Ni-NTA agarose bead column (QIAGEN), equilibrated in buffer A. The
column was washed extensively with buffer A containing 20 mM imidazole. The complex was
eluted with buffer A containing 150 mM imidazole. The eluted protein was diluted 10-fold and
was further purified by cation exchange chromatography using a 1-ml HiTrap SP HP column
(GE Healthcare). The column was equilibrated in buffer B (Table 14) and proteins were eluted
with a linear gradient from 70 mM to 2 M KOAc in buffer B. Fractions containing the protein of
interest were concentrated and loaded onto a Superose 6 10/300 (GE Healthcare) size-exclusion
chromatography column equilibrated with buffer C (Table 14) or buffer D (Table 14). The
protein complex was concentrated by centrifugation in Amicon Ultra 4-ml concentrators
(MWCO=50 kDa, Millipore) to 3 mg/mL. Protein was aliquoted, flash-frozen in liquid nitrogen
and stored at -80 °C. The similar strategy was used for purifying the five-subunit Paf1C variants.
The four-subunit Paf1 complex (Paf1C-∆Rtf1) and its variants were expressed and
purified as described for the five-subunit complex (Paf1C) except that we co-transformed
pET24b-Ctr9, pCDFDuet-1-Leo1-Paf1 and pETDuet-1-Cdc73 plasmids together in E. coli BL21
CodonPlus(DE3) RIL cells. All the components were separated by SDS-PAGE and confirmed by
mass spectrometry.
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Limited proteolysis and Edman sequencing
Limited proteolysis experiments were performed in buffer C containing 1.6 mg/mL Paf1C and
different concentration of respective protease. 0.04-0.4 ng/µL subtilisin, 1-10 ng/µL trypsin, and
2 ng/µL ArgC were incubated with Paf1C at room temperature for 2 min, 2 min, and a 5-20 min
time course, respectively. The reactions were stopped using SDS loading buffer. Samples were
analyzed by SDS-PAGE. The separated limited proteolysis products on the SDS gel were blotted
onto a PVDF membrane. The membrane was stained with Ponceau S before the fragments were
excised and sequenced using a Procise cLC (Applied Biosystems, Foster City, CA, USA).
Pull-down assay
In each pull-down assay, 5.8 µg purified Pol II was biotinylated on the Rpb3 subunit as
previously described (Kireeva et al., 2003) and immobilized on 20 µL Dynabeads M-280
Streptavidin resin (Thermo Fisher Scientific), equilibrated in buffer P (Table 14). Five fold molar
excess of purified Paf1C or/and TFIIS were incubated with immobilized Pol II or control resin at
4 °C for 1 hour. Beads were washed 5 times. Input and the bound proteins were subjected to
SDS-PAGE analysis.
Elongation complex preparation
The nucleic acid scaffold (Integrated DNA Technologies) used for transcribing mammalian RNA
polymerase II (Bernecky et al., 2016), which contains an 11 nucleotide mismatch transcription
bubble and 20 nucleotide RNA (bubble-RNA) was used to assemble Pol II-Paf1C-TFIIS EC
(template DNA sequence 5’-AAGCTCAAGTACTTAAGCCTGGTCATTACTAGTACTGCC-
3’, non-template DNA sequence 5’-
GGCAGTACTAGTAAACTAGTATTGAAAGTACTTGAGCTT-3’, and RNA sequence 5’-
UAUAUGCAUAAAGACCAGGC-3’，Table 8). 250 pmol purified Pol II was mixed with
equimolar bubble-RNA as described (Kettenberger et al., 2004). A 1.8-fold molar excess of
Paf1C-Ctr9-∆C913 and a 1.8-fold molar excess of TFIIS (DE-AA) inactive mutant were
incubated with Pol II-bubble-RNA in assembly buffer D for 15 min at 20 °C in a 65 µL reaction
volume.  We then centrifuged the reaction for 10 min at 4°C at 15,000 rpm and kept the
supernatant for size-exclusion chromatography or gradient fixation (GraFix) before XL-MS or
EM, respectively.
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Crosslinking and mass spectrometry analysis
The assembled Pol II-Paf1C-TFIIS complex was injected onto size-exclusion chromatography to
obtain a homogeneous complex. The fractions containing target complex were collected and
crosslinked at various concentrations of bis(sulfosuccinimidyl) suberate (BS3, Thermo Fisher
Scientific) to empirically determine the optimal reaction conditions. The best condition, 0.5 mM
BS3, was sufficient to convert most of individual component into a high molecular weight band
in SDS-PAGE and was chosen for final sample preparation. The Pol II-Paf1C-TFIIS at a
concentration of 425 µg/mL was crosslinked with 0.5 mM BS3 and incubated for 30 min at 30
°C. The reaction was quenched by adding 50 mM ammonium bicarbonate. The crosslinked
sample was re-purified by size-exclusion chromatography on a Superose 6 PC 3.2/300 column
(GE Healthcare) equilibrated in buffer D. Crosslinked sample was digested with trypsin as
described before (Rauhut et al., 2016).
Crosslinked peptides were enriched and divided into two parts. Both halves of the sample
were measured on an Orbitrap Fusion LC-MS/MS instrumentation platform (Thermo Fisher
Scientific) and the datasets were analyzed with pLink 1.23 (Yang et al., 2012) against a database
containing the sequences of the proteins components in the complex separately. An initial false
discovery rate (FDR) cutoff of 1% was set. E-value was calculated in this processing. To
visualize this score better, the negative logarithm of E-value was used. The final set of crosslinks
were required to satisfy 3 criteria: 1) appeared in both replicates; 2) the max score value from
each dataset was higher than 5; 3) each crosslink must have a minimal spectral count of 2 in each
dataset. The final result was subsequently visualized using the xiNET online server (Combe et
al., 2015). The same strategy was used for Paf1C XL-MS, except that the samples were
measured on an AB Sciex Triple-ToF instrument (AB SCIEX).
Gradient fixation
To reconstitute a homogeneous Pol II-Paf1C-TFIIS EC, the sucrose Gradient Fixation (GraFix)
was carried out as described (Kastner et al., 2008; Stark, 2010). Each sucrose gradient for GraFix
was generated by mixing equal volumes of light solution (Table 15) and heavy solution 1 (Table
15able 15) using a gradient mixer (Gradient Master 108, BioComp Instruments). This resulted in
a dual gradient of 10-30% sucrose and 0-0.075% glutaraldehyde in an 11 x 60 mm
ultracentrifuge tube (Beckman Coulter). Next 60 µL of the in vitro reconstituted Pol II-Paf1C-
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TFIIS EC were applied on top of the gradient. After ultracentrifugation at 32,000 rpm in a SW60
swinging bucket rotor (Beckman Coulter) for 16 h at 4 °C, 200 µL fractions of the gradient were
collected by pipetting carefully from top to bottom of the tube. Parallel sucrose gradient fractions
of samples applied to gradients either containing or lacking glutaraldehyde showed the same
sedimentation profile when analyzed by SDS-PAGE. The crosslinking reaction was quenched by
adding 0.5 M pH 7.8 aspartate to a final concentration of 12.5 mM. Micro spin chromatography
columns (Bio-Rad) were used for buffer exchange to remove sucrose, glutaraldehyde and
aspartate. The samples were concentrated using a GE concentrator (MWCO=100 kDa, GE
Healthcare) and immediately used for cryo-EM.
Cryo-EM specimen preparation and data acquisition
An FEI Vitrobot Mark IV plunger (FEI) was used for preparation of frozen-hydrated specimens.
4 µL of sample was placed onto Quantifoil Cu R3.5/1 and Cu R2/1 glow-discharged 200 mesh
holey carbon grids, which were then blotted for 8.5 s with blot force 13 to remove the excess
solution before they were flash-frozen in liquid ethane. The Vitrobot chamber was operated at
constant 4 °C and 100% humidity during blotting. The grids were transferred and stored in liquid
nitrogen before data acquisition.
Two cryo-EM datasets were acquired on a 300 keV FEI Titan Krios electron microscope
equipped with a K2 Summit direct electron counting camera (Gatan) positioned post a GIF
Quantum® energy filter (Gatan) to increase the signal-noise ratio. Automated data collection was
carried out using the TOM toolbox (Korinek et  al., 2011). Movie images were recorded at a
nominal magnification of 37,000x (corresponding to a calibrated sampling of 1.35 Å per physical
pixel) in super-resolution mode, thus yielding a pixel size of 0.675 Å per pixel. For the first
dataset, two movies were acquired in each hole and a total of 595 movie stacks with a defocus
range of -0.7 µm to -4.2 µm were collected from Quantifoil Cu R3.5/1 grids at a dose rate of 7.6
electrons per pixel per second. Each movie encompassed a total dose of ~33 electrons per Å2
with a total exposure time of 10.8 s fractionated into 27 frames. Each frame had an exposure
time of 0.4 s. For the second dataset collected from the Quantifoil Cu R2/1 grids, one movie was
acquired in each hole and 2,146 movie stacks were recorded with an exposure time of 12 s
fractionated into 30 frames, a dose rate of 4.2 electrons per pixel per second. Each frame had an
exposure time of 0.4 s, resulting in a total accumulated dose of approximate 28 electrons per Å2
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per stack. Defocus values ranged from -0.6 µm to -4.2 µm. Movie stacks from two datasets were
aligned and binned as previously described with the frame-based motion-correction algorithm to
generate drift-corrected micrographs for further processing (Li, Mooney, et al., 2013; Li, Zheng,
et al., 2013; Plaschka et al., 2015) except images were not partitioned into quadrants.
Cryo-EM image processing
Contrast transfer function (CTF) was estimated using CTFFIND3 (Mindell & Grigorieff, 2003)
and CTFFIND4 (Rohou & Grigorieff, 2015) for the datasets from Quantifoil Cu R3.5/1 grids
(R3.5) and Quantifoil Cu R2/1 grids (R2), respectively. For the R3.5 dataset, 123 aligned
micrographs were excluded because of contaminations or bad ice quality. After removing these
micrographs, we used e2boxer.py from EMAN2 package (Tang et  al., 2007) to semi-
automatically pick 84,362 particles with a box size of 2402 pixels from the remaining
micrographs. Two-dimensional (2D) reference-free classification within RELION 1.4 (Scheres,
2012) was used to remove micelles or other false positives. After this step 79,024 particles
remained. We deleted 512 aligned micrographs from the R2 dataset and semi-automatically
picked 21,301 particles using e2boxer.py from EMAN2 package with a box size of 2402 pixels.
Reference-free 2D classes were generated, and nine representative classes were low-pass
filtered to 20 Å and used as templates for autopicking (Scheres, 2015). The resulting 863,235
particles were screened manually and subjected to reference-free 2D classification, yielding
291,817 particles. We then merged particles from two datasets. 370,841 particles were used as an
input for the subsequent three-dimensional (3D) reconstruction performed with RELION 1.4
(Scheres, 2012), unless noted otherwise. A published reconstruction of bovine Pol II (Bernecky
et al., 2016) filtered to 50 Å was used as an initial reference for 3D refinement. The aligned
particles were subjected to particle polishing using RELION 1.4 (Scheres, 2014) to reduce the
noise and correct the local motion and radiation damage.
3D classifications were carried out without image alignment. The first 3D classification
was performed to separate out particles lacking the Paf1C density. This led to the dismissal of
158,422 particles. We refined the remaining 212,419 Paf1C-containing particles. Gold-standard
Fourier Shell Correlation (FSC) was calculated after the 3D refinement in RELION as described
(S. Chen et al., 2013). A 5.5 Å average resolution map was observed at the gold-standard FSC
criteria of 0.143. In the second step, a soft mask encompassing Pol II, TFIIS, Paf1C and
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DNA/RNA was generated using the ‘volume erase’ option in UCSF Chimera (Pettersen et al.,
2004) and RELION (Scheres, 2012). After 3D classification within this mask, we obtained three
Pol II-Paf1C-TFIIS maps resolving different parts of Paf1C density (parts A, B, C). The
individual classes were auto-refined using the respective masks. The complex containing part A
was refined from 114,672 particles to an average resolution of 5.7 Å. The complex containing
part B was refined from 54,722 particles to an average resolution of 5.9 Å. The complex
containing part C was refined from 43,025 particles to an average resolution of 6.2 Å. All three
maps were unsharpened and filtered according to local resolution (Cardone et al., 2013). All
structural figures were generated using UCSF Chimera (Pettersen et al., 2004) and PyMOL
(Schrödinger, LLC.).
Structural modeling
The X-ray crystallographic structure of the Pol II-TFIIS complex (PDB entry: 3PO3 (Cheung &
Cramer, 2011)) was used as the starting reference model and placed into the cryo-EM map using
UCSF Chimera (Pettersen et al., 2004). Amino acids 68-89 and 132-168 of the protrusion
domain of Rpb2 were replaced by the coordinates from the PDB entry 5C4J (Barnes et al., 2015).
Template DNA (nucleotides 1-33), non-template DNA (nucleotides 7-39) and RNA (nucleotides
7-20) were derived from the PDB entry 5FLM (Bernecky et al., 2016). The models were fitted as
rigid bodies into the density map using ‘Fit in Map’ in UCSF Chimera (Pettersen et al., 2004).
The C-terminal GTPase-like domain of Cdc73 (PDB entry: 3V46) was fitted into the map of the
complex containing part C using UCSF Chimera (Pettersen et al., 2004) and adjusted in COOT
(Emsley et al., 2010) based on the XL-MS results. We also calculated the approximate molecular
weight of the density, which is present in addition to Pol II, with Chimera using TFIIS as a
reference (Pettersen et al., 2004).
Binding assays involving analytical sucrose gradient ultracentrifugation
To investigate the binding of TFIIF and Paf1C to Pol II, analytical sucrose gradient
ultracentrifugation was carried out. A sucrose gradient was generated by mixing equal volumes
of light solution and heavy solution 2 (Table 15) using a gradient mixer (Gradient Master 108,
BioComp Instruments).
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Reconstituted Pol II-Paf1C-TFIIS EC was divided into portions. The first portion was
incubated with a 1.8-fold molar excess of TFIIF (Plaschka et al., 2016) while the other portion
was incubated with buffer D as a control. Next the reconstituted complexes were applied on top
of the gradient. After ultracentrifugation at 32,000 rpm in a SW60 swinging bucket rotor
(Beckman Coulter) for 16 h at 4 °C, 200 µL fractions were collected by pipetting carefully from
top to bottom of the tube before analyzing them by SDS-PAGE. The assay was repeated but
starting from a Pol II-TFIIF complex and then incubating with excess Paf1C-TFIIS.
4tU-Seq data collection
4-thiouracil (4tU) labeling of cellular RNA was performed as described (Sun et al., 2012) with
minor changes. 40 mL of each replicate culture were used for metabolic RNA labeling. Yeast
cells were grown in YPD medium overnight, diluted to an OD600nm of 0.1, and grown to an
OD600nm of 0.8. 4tU (Sigma, 2 M in DMSO) was added to the media at a final concentration of 5
mM, and cells were harvested after 6 min of labeling by centrifugation at 2,465 g and 30 °C for 1
min. The supernatant was discarded and the pellet resuspended in RNAlater solution
(Ambion/Applied Biosystems) and then flash frozen in liquid nitrogen. Cell number was
determined from an aliquot with a Cellometer N10 (Nexus) cell counter. Total RNA was
extracted with phenol chloroform. RNA spike-ins were added to cell pellets at the first step of
RNA purification (Schwalb et al., 2016). Amount of spike-ins was adjusted to the cell number of
each sample (120 ng of spike-in mix to 2.5 x 10^8 cells for all samples). Labeled RNA was
chemically biotinylated and purified using strepatavidin-coated magnetic beads as described
(Dolken et al., 2008). Sequencing libraries were prepared according to the manufacturer's
recommendations using the Ovation Universal RNA-Seq System (NuGEN). Libraries were
quantified with Qubit 1.0. Libraries were pooled and sequenced on an Illumina HiSeq 2500
sequencer.
4tU-Seq data analysis
Data analysis was performed as described (Schulz et al., 2013), with minor modifications.
Briefly, paired-end 50 base pair reads with additional 6 base pair of barcodes were obtained for
labeled RNA. Reads were demultiplexed and aligned to the S. cerevisiae genome (sacCer3,
version 64.2.1) using STAR (version 2.3.0) (Dobin et al., 2013). SAMTools was used to quality
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filter SAM files (Dobin et al., 2013). Alignments with MAPQ smaller than 7 (-q 7) were skipped
and only proper pairs (-f99, -f147, -f83, -f163) were selected. Further processing of the RNA-Seq
data was carried out using the R/Bioconductor environment. Piled-up counts for every genomic
position were summed up over replicates, using physical coverage i.e. counting both sequenced
bases covered by reads and unsequenced bases spanned between proper mate-pair reads. We
used a spike-in normalization strategy (Schwalb et al., 2016) to allow observation of global shifts
in RNA synthesis rates.
Fluorescence anisotropy assays with Paf1C
Paf1C-Ctr9-∆C913 and Paf1C-Ctr9-∆C913-∆Rtf1 proteins were expressed and purified as
described above.  5’ 6- fluorescein (FAM) labeled coding RNA-33 (Table 8) were obtained from
Integrated DNA Technologies and dissolved in water to 100 µM. Sequences were designed as
ssRNA, which is according to the natural sequence of exposed coding strand, and random RNA-
33 (see Table 8) refers to an artificial single strand RNA, which mimics the natural ssRNA with
the same GC content. Their sequences are 5’-FAM-
AAUAUUCAAGACGAUUUAGACGAUAAUAUCAUA-3’ and 5’-FAM-
AAUAUUCAAGCAGUAUUAGCAGUAAAUAUCAUA-3’, respectively. Protein was serially
diluted in 2-fold steps in buffer F (Table 16). Protein (12.5 µL, 23 nM- 12µM), RNA (2.5 µL, 96
nM) and 15 µL 2 times assay buffer G (Table 16) were mixed gently and incubated on ice for 10
min. The assay was brought to a final volume of 30 µL system within 8 nM florescent labeled
RNA and 10 nM- 5 µM protein. To note, we added 5 µg/mL yeast tRNA (Sigma) as a competitor
to get ride of non-specific binding. The reaction was incubated for 20 min at room temperature in
the dark. 20 µL of each solution was transferred to a Greiner 384 Flat Bottom Black Small
volume plate.
Fluorescence anisotropy was measured at 30 °C with an Infinite® M1000Pro reader
(Tecan) with an excitation wavelength of 470 nm (±5 nm), an emission wavelength of 518 nm
(±20 nm) and a gain of 72. All measurements were repeated three times and results were
averaged and subsequently analyzed with GraphPad Prism Version 6. Error bars are
representative of the standard deviation from the mean of triplicates.
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Transcription elongation assay
For transcription elongation assay, tailed templates as listed and indicated were used (Table 16).
RNA was labeled with 5’ 6- fluorescein (FAM). Tailed template DNA and FAM-RNA were
annealed as described. Purified Pol II was mixed with 2-fold excess template DNA-RNA and
incubated at 25 °C at 600 rpm for 10 min. Then 2-fold excess of non-template DNA was added
and incubated at 25 °C at 600 rpm for 10 min, the Pol II-templates was diluted to 500 nM using
TB buffer (Table 17). Four types of ribonucleotide (NTPs) were mixed in equimolar amount in
water to a concentration of 25 mM and diluted to 2.5 mM with TB buffer. Each reaction was
performed in a 10-µL system, containing 100 nM Pol II-templates. Additional proteins or
equivalent volume of TB was added. 2 µL of 2.5 mM NTPs was added to a final concentration of
0.5 mM to star the reaction and incubated in a pre-heated Thermocycler (Biometra) for 10 min at
37 °C.  The reaction was quenched by adding 2x stop buffer (Table 17) and further incubated at
37 °C for 1 h and 95 °C for 5 min. The 20% TBE urea gel was pre-run in 1x TBE buffer (Table
17) for 15 min at 300 V before the sample was loaded. The gel was run for 2 h at 300 V in dark
and imaged with Typhoon FLA 9500 (GE Healthcare).
2.2.4 Bioinformatics tools
Gene and protein sequences were obtained from the NCBI or S. cerevisiae genome (SGD)
databases. ClustalW (Larkin et al., 2007) and Clustal Omega (Sievers et al., 2011) were used for
sequence alignments. Psipred was used to analysis the secondary structure predictions(Jones,
1999). HHpred (Alva et al., 2016; Hildebrand et al., 2009; Meier & Soding, 2015; Remmert et
al., 2011; Soding, 2005; Soding et al., 2005) and SMART (Letunic et al., 2015) were used to
predict the motifs and low complexity regions. ProtParm online software was used to predict the
protein specific parameters.
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3. Results and Discussion
3.1 Recombinant Paf1 complex (Paf1C)
Figure 3: Predicted domain structure of the five Paf1C subunits from S. cerevisiae. The predicted
TPR motifs (yellow) and low complexity regions (green) were defined using SMART (Letunic et al.,
2015). Structurally resolved regions are indicated with black lines. The Plus3 domain in Rtf1 (red) binds
single-stranded DNA (de Jong et al., 2008) and the Spt5 CTR (Wier et al., 2013). A Paf1C-interacting
region (orange) in Rtf1 (Warner et al., 2007) was confirmed in this work.
Paf1C from the yeast S. cerevisiae has a molecular weight of 340 kDa and consists of
five subunits, Paf1, Leo1, Ctr9, Cdc73, and Rtf1 (Figure 3). Analysis of the primary and
secondary structures of these subunits (Alva et al., 2016; Hildebrand et al., 2009; Letunic et al.,
2015; Meier & Soding, 2015; Remmert et al., 2012; Soding, 2005; Soding et al., 2005) predicted
known structured domains (Amrich et al., 2012; H. Chen et al., 2012; X. Chu et al., 2013; de
Jong et al., 2008; Wier et al., 2013) and eight tetratrico peptide repeats (TPR) in Ctr9 (Figure 3).
In addition, multiple regions of low sequence complexity were detected in all Paf1C subunits
except Cdc73, consistent with the known flexibility of Paf1C.
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Figure 4: Preparation of recombinant Paf1C. a, Size-exclusion chromatogram (Superose 6 10/300; GE
Healthcare) of recombinant full-length Paf1C indicates a pure complex free of nucleic acids. b,
Coomassie-stained SDS-PAGE analysis of recombinant five-subunit Paf1C after size-exclusion
chromatography reveals the presence of all five subunits in apparently stoichiometric amounts. Molecular
weight markers are indicated on the left. The identity of subunits was confirmed by mass spectrometry. c,
Same as b but for purified complex Paf1C-Ctr9-∆C913.
To study Paf1C structurally, we established preparation of pure recombinant Paf1C after
co-expression of its subunits in E. coli (Figure 4a, 4b, and also see 2.2.3 Specific methods). The
five Paf1C subunits were co-expressed from three vectors in E. coli and the complex purified
using chromatographic methods (Figure 4a). We obtained approximately 0.4 mg of pure Paf1C
per liter of E. coli cell culture. Purified Paf1C contained all five subunits in apparently
stoichiometric amounts (Figure 4b).
3.2 Paf1C structural core and flexible periphery
To map a stable structural core of Paf1C, we identified a Ctr9 variant that lacked 164 amino
acids at its C-terminus (Ctr9-∆C913) but was sufficient to form a stable complex with the other
subunits after co-expression (Paf1C-Ctr9-∆C913) (Figure 4c).
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Figure 5: Preparation of various Paf1C recombinant proteins. a-c, Coomassie-stained SDS-PAGE
analysis of (a) Paf1C-Ctr9-∆C913-∆Rtf1, (b) core Paf1C, and (c) core Paf1C-Rtf1∆N441 after size-
exclusion chromatography (Superose 6 10/300; GE Healthcare) reveals four-subunit and five-subunit
Paf1C variants. Molecular weight markers are indicated on the left. The identity of subunits was
confirmed by mass spectrometry. d, Limited proteolysis using subtilisin, trypsin, and ArgC under either
various concentrations or reaction times shows Paf1C contains many flexible regions.
We also obtained a recombinant Paf1C variant that additionally lacked subunit Rtf1
(Paf1C-Ctr9-∆C913-∆Rtf1, Figure 5a). To further delineate the core of Paf1C, we used limited
proteolysis and Edman sequencing (Figure 5d and see 2.2.3 Specific methods) and designed
deletion mutants of the remaining three subunits. Using iterative truncation, co-expression, and
co-purification, we defined a structural core of Paf1C that additionally lacked the C-terminal
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region of Paf1 and both terminal regions of Leo1. The resulting Paf1C core contained Ctr9-
∆C913, Paf1-∆C361, Leo1-∆N118-∆C376, and Cdc73 (Figure 5b). The defined Paf1C core
comprises 1,926 amino acid residues out of a total of 2,937 residues, i.e. 65% of the total protein
mass. Thus one third of Paf1C forms flexible regions on the periphery of the complex.
3.3 Paf1C and TFIIS bind Pol II synergistically
To investigate whether purified Paf1C binds to yeast Pol II in vitro, we performed pull-down
assays using biotinylated Pol II coupled to streptavidin beads (see 2.2.3 Specific methods).
Paf1C interacted with Pol II, albeit in a substoichiometric manner (Figure 6a, lane 4).
Considering the known interaction of human Paf1C with TFIIS (Kim et  al., 2010), we tested
whether TFIIS enhances Pol II-Paf1C binding. Indeed, TFIIS strongly enhanced binding of
Paf1C to Pol II in our assay (Figure 6a, lane 5). In contrast, an N-terminal deletion variant of
TFIIS lacking 130 residues (TFIIS-∆N130) could not enhance Pol II-Paf1C interaction (Figure
6b, lane 7 and 8). These results suggest that the N-terminal domain I of TFIIS, which is mobile
in the Pol II-TFIIS structure (Kettenberger et al., 2003), interacts with Paf1C to increase its
affinity to Pol II. In addition, Paf1C lacking the C-terminal domain of Ctr9 and Rtf1 retained Pol
II binding (Figure 6c, lane 6 and 8) and TFIIS-enhanced binding (Figure 6c, lane 7 and 9). These
results show that recombinant Paf1C interacts with Pol II in vitro, that this interaction does not
require Rtf1, and that it is strongly enhanced by TFIIS.
49
Figure 6: Analysis of Pol II-Paf1C-TFIIS EC interactions. SDS-PAGE analysis of Pol II-Paf1C-TFIIS
binding assays. Subunits from Pol II, Paf1C, and TFIIS are labeled in black, pink, and green, respectively.
a, TFIIS enhances Pol II-Paf1C binding. Lane 4 and 5 show Pol II-Paf1C and Pol II-Paf1C-TFIIS
interactions, respectively. When TFIIS is present, Pol II and Paf1C bind better. b, TFIIS, but not TFIIS-
∆N130, cooperatively binds to Pol II-Paf1C (lane 7 and 8). c, Paf1C lacking Rtf1 and the C-terminal
domain of Ctr9 retains Pol II binding (lane 6 and 8) and TFIIS-enhanced binding (lane 7 and 9).
50
3.4 Cryo-EM analysis
To determine the structure of Paf1C bound to a Pol II EC, we prepared a complex containing the
complete 12-subunit Pol II (Sydow et al., 2009), a DNA-RNA scaffold (Bernecky et al., 2016),
full-length TFIIS carrying two point mutations that render it inactive in RNA cleavage
stimulation (Cheung & Cramer, 2011; Kettenberger et al., 2003) (see 2.2.3 Specific methods),
and recombinant Paf1C lacking the Ctr9 C-terminus (Paf1C-Ctr9-∆C913), which is more stable
than Paf1C with full-length Ctr9. The complex contained all 18 polypeptides in apparently
stoichiometric amounts after sucrose gradient ultracentrifugation (Figure 7a). After gradient
fixation (Kastner et al., 2008; Stark, 2010) (Figure 7b), the sample contained single particles, as
revealed by EM in negative stain, and was subjected to cryo-EM data collection. A total of 2,741
movie stacks were collected on a Titan Krios equipped with a Gatan K2 direct electron detection
device (Figure 8).
Figure 7: Pol II-Paf1C-TFIIS sample preparation for cryo-EM. a, SDS-PAGE analysis (Coomassie
staining) of Pol II-Paf1C-TFIIS EC after sucrose gradient ultracentrifugation. Subunits from Pol II and
Paf1C are labeled in black and pink, respectively. The inactive variant of TFIIS is labeled in green. The
asterisk marks a degradation product of Rpb1. b, SDS-PAGE analysis of crosslinked Pol II-Paf1C-TFIIS
after sucrose gradient fixation. A shift to higher molecular weight indicates successful crosslinking.
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Figure 8: A representative cryo-EM micrograph of Pol II-Paf1C-TFIIS. 50 nm scale bar is included
as a size reference.
Figure 9: 2D cryo-EM class averages of Pol II-Paf1C-TFIIS. Ten representative reference-free two-
dimensional (2D) cryo-EM class averages reveal the known flexibility of the Pol II stalk subcomplex
Rpb4/7 (white arrow) and density for Paf1C (pink arrow).
From the cryo-EM micrographs, a total of 947,597 particles were extracted. Particle
images were processed and subjected to reference-free two-dimensional (2D) classification in
RELION (Scheres, 2012), yielding 370,841 particles after clearance. In several 2D classes,
smeared densities for the peripheral Paf1C and the Pol II stalk subcomplex Rpb4-Rpb7 were
observed on the polymerase surface (Figure 9). As a reference we used a reconstruction of
bovine Pol II (Bernecky et al., 2016) filtered to low resolution (50 Å). After particle polishing in
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RELION, 3D-classification was used to separate out 158,422 particles that contained Pol II-
TFIIS EC that lost Paf1C. We refined the remaining 212,419 Paf1C containing particles, which
led to a structure at 5.5 Å global resolution that contained the Pol II-TFIIS EC that closely
resembled the crystal structure (Figure 10, Figure 11c, 11d, and Supplementary Figure 3).
Further sorting resulted in three different Pol II-Paf1C-TFIIS EC reconstructions that we refer to
as A, B, and C (Figure 10 and see 2.2.3 Specific methods). These reconstructions showed
average resolutions of 5.7 Å, 5.9 Å and 6.2 Å, respectively (FSC=0.143, Figure 11a, 11b, and see
Specific methods) and enabled rigid-body fitting of the Pol II-TFIIS crystal structure (Barnes et
al., 2015; Cheung & Cramer, 2011) and the DNA-RNA model (Bernecky et al., 2016) (Figure
11c, 11d, and see 2.2.3 Specific methods). The reconstructions did not reveal structural changes
within the Pol II-TFIIS complex compared to the known crystal structure.
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Figure 10: Computational sorting of cryo-EM particle images. Particles were 3D-classified in
RELION to reveal additional features of Pol II-Paf1C-TFIIS after 2D classification. Classifications were
performed without image alignment by global 3D classification using a spherical mask. After global
classification, we separated Pol II-Paf1C-TFIIS and Pol II-TFIIS complexes. We further merged two
classes with additional density near the protrusion. After auto-refinement and subsequent 3D
classification with a mask encompassing Pol II-Paf1C-TFIIS, we obtained three structures displaying
different parts of Paf1C. Pol II and scaffold are colored in grey, whereas TFIIS is in green. Parts A, B,
and C of Paf1C are in pink, orchid and purple, respectively. To visualize the density from Paf1C, a front-
side view is related by one rotation from the front view (Cramer et al., 2000) as indicated.
54
Figure 11: Cryo-EM reconstruction of Pol II-Paf1C-TFIIS subclasses.  a, Angular distribution of Pol
II-Paf1C-TFIIS reconstructions A, B, and C from cryo-EM single particle reconstructions. Red dots
indicate at least one particle was assigned within 1° of the point. Black shading indicates the number of
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particles assigned to a given view. b, The FSC curves for the Pol II-Paf1C-TFIIS subclasses. Color
scheme: Pol II-Paf1C-TFIIS reconstruction A, red; reconstruction B, blue; reconstruction C, dark green.
The resolution of the reconstructions using the Fourier shell cutoff at 0.5 and 0.143 is shown. c, TFIIS
EM density (grey mesh) from the unsharpened Pol II-Paf1C-TFIIS. Crystal structure derived from 3PO3
is fitted. A schematic diagram of TFIIS domains is shown below. Domain II, linker, and domain III are
represented in green, yellow, and orange boxes. Point mutations of two functionally essential acidic
residues are indicated. No density was observed for TFIIS residues 1-148 containing domain I and a
linker, which are labeled with dashed lines due to their flexibility. d, EM  density  for  the  DNA-RNA
hybrid and up- and downstream DNA of Pol II-Paf1C-TFIIS (grey mesh) with the final model
superimposed. Color scheme: non-template DNA, cyan; template DNA, blue; RNA, red; active site,
magenta. e-g, Top, front and front-side views of unsharpened (e) Pol II-Paf1C-TFIIS reconstruction A, (f)
reconstruction B, and (g) reconstruction C colored by local resolution. All the densities are shown at the
same threshold level and locally normalized. Resolution bars are shown on the left.
3.5 Architecture of Pol II-Paf1C-TFIIS elongation complex
Reconstructions A, B, and C revealed different portions of Paf1C on the Pol II surface that we
refer to as Paf1C parts A, B, and C, respectively. The observation that these three parts of Paf1C
could only be observed in different cryo-EM reconstructions shows that their relative orientation
is flexible. Due to this mobility on the Pol II surface, the local resolution of Paf1C was low
(Figure 11e-g). When contoured at a level where no noise peaks are observed, the volumes of
parts A, B, and C could account for approximately 50, 45, and 90 kDa of folded protein. Because
part C overlaps with part A by approximately 10 kDa, a total of ~175 kDa of Paf1C is visible by
cryo-EM, corresponding to ~50% of the total mass of Paf1C, suggesting that most of the
structured core (65%) is revealed. We combined reconstructions A-C into a composite map that
is further interpreted below.
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Figure 12: Cryo-EM structure of Pol II-Paf1C-TFIIS EC. Two views of the EM density for the Pol II-
Paf1C-TFIIS  EC  and  the  fitted  structure  of  the  Pol  II-TFIIS  EC.  The  view  on  the  left  is  from  the  top
(Cramer et al., 2000), and the view on the right is related by two rotations as indicated. Density for the
Pol II-TFIIS EC subcomplex is shown as a silver semi-transparent surface. The composite electron
density for Paf1C is shown as a solid surface colored in pink, magenta, and purple for Paf1C parts A, B,
and C, respectively. The same threshold level in Chimera was used to contour densities. The structure of
the Pol II-TFIIS EC is shown in ribbon representation (non-template DNA, cyan; template DNA, blue;
RNA, red, TFIIS, green; Rpb2 lobe, yellow; Rpb2 protrusion, orange; Rpb2 external 2, green; Rpb3, red;
Rpb11, yellow).
Paf1C binds to the outer surface of Pol II on the Rpb2 side, spanning from the Rpb2 lobe,
external 2, and protrusion domains to subunit Rpb3 and reaching near the rim of the funnel
opposite the active center cleft (Figure 12). Paf1C part A contacts mainly the external 2 domain
and likely the protrusion domain of Rpb2. Part B contacts the protrusion and part C contacts
Rpb11 and Rpb3 around its helix α3. Part B also bridges between parts A and C, which
otherwise do not contact each other. Taken together, cryo-EM revealed that the Paf1C core may
be divided in three parts, with parts A and C contacting Pol II at the Rpb2 lobe and Rpb3,
respectively, and part B bridging between parts A and C.
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3.6 Crosslinking analysis
To confirm the contacts of Paf1C with Pol II, and to assign Paf1C subunits to the three parts of
Paf1C, we subjected the Pol II-Paf1C-TFIIS EC to chemical crosslinking coupled to mass
spectrometry (XL-MS). We used the crosslinking reagent bis(sulfosuccinimidyl) suberate (BS3),
which reacts with lysine side chains and N-termini. In each crosslinking dataset, two replicates
were measured. All the spectra of the crosslinks were filtered at a false discovery rate (FDR)
cutoff of 1% and the maximum score value (negative logarithm of E-value) higher than 5. Each
crosslink was required to have a minimal spectral count of 2 in the two replicates of each dataset
(see 2.2.3 Specific methods). We obtained 239 unique inter-subunit crosslinks (Figure 13, Table
18, and Supplementary Table 13).
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Table 18: Summary of BS3 crosslinks in Pol II-Paf1C-TFIIS EC. The numbers of inter-protein crosslinks
are given. Inter-protein crosslinks between Pol II subunits are not shown here for clarity. Each unique
crosslink is identified by more than one crosslink. BS3 is a crosslinker with 11.4 Å spacer arm and reacts
efficiently with amino groups (lysine and N-terminus).
Protein 1 Protein 2
Unique Crosslinks
BS3
Paf1C Pol II 49
Ctr9 Rpb1 1
Rpb3 1
Rtf1 Rpb2 1
Leo1 Rpb1 2
Rpb2 35
Paf1 Rpb2 3
Cdc73 Rpb11 4
Rpb2 1
Rpb3 1
TFIIS Paf1C 2
Leo1 2
Paf1C Paf1C 136
Ctr9 Rtf1 36
Leo1 7
Paf1 20
Cdc73 19
Rtf1 Leo1 6
Paf1 19
Leo1 Paf1 25
Cdc73 4
Pol II Pol II 47
Pol II TFIIS 5
Total 239
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Figure 13: Crosslinking analysis of Pol II-Paf1C-TFIIS EC. a, Network diagrams of pairwise
crosslinks (black lines) obtained after incubation of Pol II-Paf1C-TFIIS EC with BS3. The left diagram
depicts inter-subunit crosslinks between Pol II and Paf1C, Pol II and TFIIS, and between Paf1C and
TFIIS. The right diagram depicts crosslinks between Paf1C subunits. Crosslinks between Pol II subunits
were excluded for clarity. Paf1C subunits colored as in Figure 3. In addition, the regions of protrusion,
lobe, and external 2 in Rpb2 are indicated with orange, yellow, and green bars below Rpb2 diagram,
respectively. b, Cα-Cα distance distribution of observed Pol II-Pol II and Pol II-TFIIS crosslinks for
lysine residues that were resolved in the Pol II-TFIIS crystal structure. These crosslinks serve as a
positive control for our crosslinking data. Asterisks indicate crosslinks to flexible protein regions. c,
Crosslinks between Pol II and TFIIS (black lines) are consistent with the known Pol II-TFIIS complex
crystal structure. Color coding as in Figure 12. d, Position of the Cdc73 C-terminal GTPase-like domain
(purple) contacting Rpb3. The crystal structure of the GTPase-like domain was docked into density of the
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correct size and oriented according to crosslinks to Rpb3 and Rpb11 (black lines). Paf1C density is shown
as an outline in the same orientation as in Figure 12. View is from the top.
We first mapped crosslinks between Pol II subunits and between Pol II and TFIIS onto
the Pol II-TFIIS EC crystal structure (Cheung & Cramer, 2011). The Cα-Cα distances between
crosslinked residues were within the allowed distances of 30 Å for 35 out of 38 inter-subunit
pairs. The other 3 crosslinks that showed longer Cα distances fell in regions with structural
flexibility and higher crystallographic B-factors (Figure 13b, 13c, and Supplementary Table 3).
In addition, we observed that Leo1 was crosslinked to two lysine residues (K78, K80) in domain
I of TFIIS, consistent with our pull down assays (see above). These results provided an internal,
positive control for our crosslinking approach.
3.7 Paf1C subcomplex architecture
The data also contained 136 inter-subunit crosslinks within Paf1C (Figure 13a, Table 18, and
Supplementary Table 3). These included 25 crosslinks between Paf1 and Leo1, consistent with
the known dimerization of Paf1 and Leo1 subunits. Crosslinks of the Leo1 residue K225 to Paf1
residues K167 and K170 can be rationalized with the Paf1-Leo1 X-ray structure. A total of 27
crosslinks were observed between the Paf1-Leo1 dimer and Ctr9, revealing their proximity. The
subassembly Paf1-Leo1-Ctr9 crosslinked to the C-terminal regions of Cdc73 and Rtf1.
Consistent with this, the C-terminal region of Rtf1 suffices to bind Paf1C, because its co-
expression with the Paf1C core resulted in a stable complex (Figure 5c). We also crosslinked free
Paf1C and the obtained crosslinking pattern was similar (Supplementary Figure 2 and
Supplementary Table 2).
We also obtained 49 inter-subunit crosslinks between Paf1C and Pol II (Figure 13a, Table
18, and Supplementary Table 3). 44 of these crosslinks map to the Rpb2 lobe, protrusion, and
external 2 domains, and subunits Rpb3 and Rpb11 (Supplementary Table 3), consistent with the
location of Paf1C observed by cryo-EM. Extensive crosslinking between the Paf1-Leo1 dimer
and the Pol II protrusion and lobe show that the Paf1-Leo1 heterodimer resides in part A.
Crosslinks between Cdc73 and Pol II subunits Rpb3 and Rpb11 reveal that Cdc73 resides in part
C. Indeed, part C contains a globular density that contacts Rpb3 and corresponds in size to the
crystal structure of the C-terminal GTPase-like domain of Cdc73 (Amrich et al., 2012) (Figure
13d). We could fit this crystal structure to the globular density (Pettersen et al., 2004) such that
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the crosslinks between Cdc73 and Pol II were explained. Three crosslinks occurred between the
fitted structure and Rpb3, whereas Cdc73 residues in the adjacent N-terminal tail crosslinked to
the nearby Rpb11 subunit (Figure 13d). Finally, Ctr9 can be assigned to part B because it
crosslinks to both, Paf1-Leo1 in part A and Cdc73 in part C. Thus Ctr9 bridges between Paf1-
Leo1 and Cdc73, which both contact Pol II. Ctr9 did not crosslink efficiently to Pol II, consistent
with the bridging density B that does not reach the Pol II surface.
Combining the crosslinking data with the cryo-EM results and our mapping of flexible
regions in Paf1C enabled us to derive the overall architecture of Paf1C bound to Pol II. The sizes
of the EM densities can be reconciled with the Paf1C subunit molecular weights as follows. Part
A reveals only about half of the Paf1-Leo1 heterodimer (~50 out of 105 kDa), the other half is
flexible. Part B reflects about half of the mass (~45 kDa) of Ctr9-∆C913 (105 kDa), whereas the
other half of Ctr9 resides in part C, which is much larger than the Cdc73 GTPase-like domain
alone (~20 kDa). Finally, Rtf1 (65 kDa) remains flexible.
3.8 Competitive Pol II binding of Paf1C and TFIIF
Superposition of the Pol II-Paf1C-TFIIS EC onto our previously reported Pol II initiation
complex structure (Plaschka et al., 2016) reveals a clash between Paf1C part A and the
dimerization domain of the initiation factor TFIIF bound to the outer lobe of Pol II at an
overlapping position (Figure 14a). This suggested that binding of Paf1C and TFIIF to Pol II is
competitive or mutually exclusive. To investigate this, we performed binding assays using
analytical sucrose gradient ultracentrifugation (see 2.2.3 Specific methods). We incubated
preformed Pol II-Paf1C-TFIIS complex with a 1.8-fold molar excess of TFIIF and separated the
resulting complexes on a 10-30% sucrose gradient. Based on subsequent SDS-PAGE analysis,
we estimate that TFIIF replaced Paf1C in about half of the Pol II complexes (Figure 14b). When
we instead incubated preformed Pol II-TFIIF complex with Paf1C and TFIIS, some TFIIF was
displaced, TFIIS was able to join the complex, and Paf1C bound to a low extent (Figure 14c).
These results indicate that Paf1C and TFIIF bind to Pol II in a competitive manner, consistent
with the cryo-EM reconstruction.
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Figure 14: Paf1C and TFIIF compete for Pol II binding. a, Positioning the initiation factor TFIIF
dimerization domain as in the Pol II initiation complex (PDB accession: 5FYW) (Plaschka et al., 2016)
onto the Pol II-Paf1C-TFIIS EC cryo-EM reconstruction results in a clash of TFIIF with Paf1C (top
view). Colors as in Figure 12. The TFIIF dimerization domain is colored in medium purple (TFIIF
subunit Tfg1) and plum (TFIIF subunit Tfg2).  A close-up view of the clashing region is shown on the
right. b-c, SDS-PAGE analysis of TFIIF and Paf1C competitive binding to Pol II after analytical sucrose
gradient ultracentrifugation. In each panel, the gels on the left depict complexes without competitor
protein. The gels on the right represent complexes formed after competitor addition. In panel b, a 1.8-fold
molar excess of TFIIF was added to preformed Pol II-Paf1C-TFIIS EC. In panel c, Paf1C-TFIIS was
added to preformed Pol II-TFIIF complex.
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3.9 Paf1C is globally required for Pol II transcription
Thus far it had not been demonstrated whether Paf1C is a general transcription factor in yeast.
To investigate whether Paf1C is globally required for transcription in vivo, or whether it has
gene-specific functions, we monitored RNA synthesis with 4tU-Seq in yeast (Eser et al., 2016;
Miller et al., 2011; Schulz et al., 2013). This method uses metabolic RNA labeling with 4-
thiouracil (4tU) coupled to strand-specific sequencing of labeled, newly synthesized RNA. We
used 4tU-Seq to monitor RNA synthesis in strains lacking either Paf1 (ΔPaf1) or Rtf1 (ΔRtf1),
and compared this to a wild-type (WT) strain using global normalization based on spike-in
probes(Schwalb et al., 2016). Two biological replicates were measured. We found that knockout
of Paf1 or Rtf1 led to a strong, global decrease in synthesis of mRNA transcripts (Figure 15),
showing that Paf1C is globally required for normal Pol II transcription.
Figure 15: Paf1C is globally required for Pol II transcription in yeast. Left panel: coverage of newly
synthesized RNA measured by 4tU-seq in WT (solid blue line), ∆Rtf1 (dashed red line), and ∆Paf1 yeast
cells (dashed green line). 4tU-seq signals were globally normalized using spike-in probes. The gene body
is defined as the region spanning from the transcription start site (TSS) to the polyadenylation (pA) site
and is depicted as a grey box. Right panel: box plot showing the expression fold change of read counts for
∆Paf1 and ∆Rtf1 vs. the WT strain. Dashed lines indicate median fold (0.52 for ∆Paf1 and 0.23 for
∆Rtf1). The majority of mRNAs are below 1 (indicated by the solid black line). Decreased mRNAs make
up 85% for ∆Paf1 and 94% for ∆Rtf1 of all mRNAs with a coverage of at least 2 in the WT strain.
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3.10 Paf1C binds RNA independent of Rtf1
Considering that Leo1 subunit and Rtf1 subunit both have RNA binding capacity (Dermody &
Buratowski, 2010), we investigated whether Paf1C lacking Rtf1 influences the binding to RNA.
We used fluorescent anisotropy titration assays. We first analyzed Paf1C-Ctr9-∆C913 and
Paf1C-Ctr9-∆C913-∆Rtf1 with a 33 nucleotide natural coding RNA sequence bearing a 5’ 6-
FAM label.  We found Paf1C binds the RNA with a Kd of ~0.43± 0.02 µM, whereas Paf1C-
Ctr9-∆C913-∆Rtf1 bound more weakly with a Kd of ~1.17± 0.10 µM. Our data reveals Paf1C
binds to RNA, and that Rtf1 subunit plays a key role. To gain further insights, we designed a
random RNA sequence, in which a few nucleotides were modified but with the same GC content
compared to the natural coding RNA. The result we observed indicates Paf1C also binds strongly
to random sequence RNA, with Paf1C-∆Rtf1 binding weaker, suggesting a universal function
(Figure 16). These results also suggest Paf1C binding to RNA does not only rely on Rtf1.
Unfortunately, we couldn’t purify Leo1 depletion or Paf1 depletion variants and test their
binding to RNA, because they are crucial subunits for forming Paf1C.
Figure 16: Rtf1 is very important for Paf1C binding to RNA. Purified Paf1C-Ctr9-∆C913 and Paf1C-
Ctr9-∆C913-∆Rtf1 variants were used in this fluorescent anisotropy assay to test the binding to natural
coding RNA (up) and random RNA (bottom), respectively. The color code shows the different binding of
Paf1 complexes to RNA with binding affinities (Kd).
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4. Conclusion and Outlook
From this thesis described here, I showed that we were able to purify the 340 kDa Paf1C
recombinantly, and used a combination of cryo-EM and crosslinking to show that Paf1C forms a
trilobal architecture with three parts. Parts A and C contain Paf1-Leo1 and Cdc73, respectively,
and contact Pol II near the external domain 2 and Rpb3, respectively. Ctr9 forms part B and
extends into part C, and forms a flexible bridge between parts A and C that is not directly
contacting Pol II. These results provide a framework for integrating published data. Ctr9 is
known to form a scaffold that bridges between the Paf1-Leo1 heterodimer and Cdc73 as
predicted (X. Chu et al., 2013). The Cdc73 GTPase-like domain binds Pol II, consistent with the
requirement for this domain to recruit Paf1C to chromatin (Amrich et al., 2012). Most of Rtf1 is
flexible, including the Plus3 domain that binds the phosphorylated C-terminal region (CTR) of
Spt5 (Wier et al., 2013), which is also flexibly connected to the EC (Figure 17). My results also
explain how Paf1C and TFIIS can cooperatively bind to Pol II (Kim et al., 2010). Pull down
assays show that TFIIS facilitates Pol II-Paf1C binding via its domain I, I observe crosslinking
between Leo1 and TFIIS domain I, and this interaction apparently occurs near the jaw-lobe
module of Pol II. We arrive at an overall architecture of the Paf1C on the Pol II elongation
complex.
The results elucidate the general transcription cycle, because Paf1C is generally required
for transcription in vivo. In particular, they provide insights into the transition from transcription
initiation to elongation, when initiation factors are replaced by elongation factors on the Pol II
surface (Guo & Price, 2013; Kwak & Lis, 2013; Mayer et al., 2010). In the initiation complex,
association of Paf1C with Pol II is impaired because TFIIF blocks the site for binding of Paf1C
part A. Similarly, TFIIE blocks the site for binding the elongation factor Spt4-Spt5 on the clamp
(Grohmann et al., 2011; Martinez-Rucobo et al., 2011). These observations indicate why Paf1C
and Spt4-Spt5 bind the EC only upon disassembly of the initiation complex. The individual
interactions of these elongation factors with Pol II appear to be weak, but may be facilitated by
interactions between them (Mayekar et al., 2013; Qiu et al., 2012), and between Paf1C and
TFIIS (Kim et al., 2010). I note that the second contact of Paf1C with Pol II, formed by part C,
in particular the GTPase domain of Cdc73, with Rpb3, appears unique as it does not overlap with
known factor positions on Pol II. This contact may therefore help to retain Paf1C in the
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elongation complex when TFIIF reassembles during elongation (Zawel et al., 1995). These
studies provide a framework for further dissection of the multiple functions of Paf1C in
transcription.
Figure 17: Model of the Pol II EC with bound elongation factors. Summary of our current
understanding of elongation factor location and interactions on the Pol II EC surface. In addition to direct
Pol II interactions by domains in TFIIS, Spt5, and Paf1C, elongation factors contain many flexible
domains and regions that interact. In particular, the Paf1-Leo1 heterodimer may contact the N-terminal
domain I of TFIIS and the C-terminal region of Rtf1 is anchored to Paf1C mainly by Paf1 and Ctr9
subunits shown in XL-MS, whereas its Plus3 domain binds the flexible C-terminal repeat domain (CTR)
of Spt5. The N-terminal tail of Rtf1 is import for recruiting the chromatin remodeler Chd1 (Simic et al.,
2003). Dash lines in this model indicate flexible regions.
Although an initial understanding of the highly flexible Pol II-Paf1C-TFIIS EC emerges
in this study, there are still many unanswered questions.
For example, what is the near-atomic structure of Paf1C? So far, the crystal structural
studies on this complex have been limited to a few domains. After much effort towards getting
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this complex, attempts to crystallize the Paf1C and it variants failed, mainly due to its many
flexible regions. Even the solid core of Paf1C didn’t lead to a good crystal. We obtained crystals
when we used Paf1C-Ctr9-∆C913-∆Rtf1 with chymotrypsin in situ proteolysis.  The crystals
diffracted to 7 Å resolution, which was insufficient to resolve the structure. We expect that x-ray
free electron laser (XFEL) could be helpful. Also, as better imaging hardware, phase-plates, and
other technologies are developing, solving this ‘flexible’ complex, with a molecular weight less
than 0.5 MDa, to a near-atomic resolution will be possible using cryo-EM. Moreover, a higher-
resolution structure of Pol II-Paf1C-TFIIS would reveal the exact contacting residues between
Pol II and Paf1C, and will make clear whether there are any conformational changes between
free Paf1C and Pol II-bound Paf1C, which will help us better understand its mechanism.
To get high-resolution structures, more transcriptional factors besides TFIIS may be
needed to stabilize Paf1C, especially the flexible regions. This leads to another question; what
are the factors responsible for productive transcription elongation? We already knew that Spt4-
Spt5 is a key complex in regulating transcription elongation, and the CTR domain of Spt5
physically interacts with Paf1C via the plus3 domain of the Rft1 subunit (Wier et al., 2013). Pol
II provides vital links between them acting as a bridge. In the human system, the regulation of
transcription elongation is more sophisticated. P-TEFb not only phosphorylates the CTR to
facilitate the recruitment of Paf1C, but also phosphorylates NELF to release Pol II from the
paused state (Kwak & Lis, 2013). Studies on a yeast Pol II-Paf1C-TFIIS-Spt4-Spt5 complex will
be instructive for understanding these mechanisms in human.
Does Paf1C play any role in backtracking? TFIIS has at least a dual role: to help normal
transcription elongation, and to stimulate the cleavage activity of Pol II (Cheung & Cramer,
2011; Kettenberger et al., 2003, 2004). In our study, we observed that TFIIS enhances the Pol II-
Paf1C binding most likely via its domain I. What role does Paf1C play together with TFIIS?
Does it enhance the elongation rate or influence the cleavage activity? From our in vitro
transcription elongation assays, we hardly see any effect of Paf1C during transcription
elongation in the presence or absence of TFIIS. However, so far we focused only on in vitro
analysis, how Paf1C functions together with TFIIS in vivo remains unclear.
Another question is about the composition of the Paf1C in yeast. What role does Ski8
play? Ski8 is a WD repeat protein. Ski8 is a 44-kDa protein (PDB entry: 1SQ9) (Madrona &
Wilson, 2004). In yeast, Ski8 is reported as a component of Ski complex and to primarily
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function in the regulation of exosome-mediated, 3' to 5' degradation of damaged mRNA and
meiosis (Halbach et al., 2013; Madrona & Wilson, 2004). As we know, Paf1C is conserved from
yeast to human. Ski8 is a component of human Paf1C instead of Rtf1 (Cao et al., 2015; X. Chu
et al., 2013; Rozenblatt-Rosen et al., 2009; Zhu et al., 2005). In contrast, in yeast Ski8 has not
been reported to be a Paf1C subunit, but it nevertheless shows genetic interaction with Cdc73
(Wilmes et al., 2008). Our study already suggested that Rtf1 is not an essential subunit for
forming Paf1C in agreement with that Rtf1 has an independent role during the transcription
elongation (Cao et al., 2015). Why is the composition of Paf1C from the two species different?
Is there any evolutionary significance to this difference? We could expand our research to
include Ski8, to better understand its functions in the two species, and compare them.
Furthermore, we could also investigate Paf1C from other species to see if there are any
evolutionary trends.
The transition from initiation to elongation is poorly understood. The transition is always
accompanied by a series of dynamic processes, including the exchange of factors. Learning what
the intermediate complexes are will greatly help us comprehend this process.
All these lead to an advanced question; what are the mechanisms Paf1C uses to facilitate
chromatin transcription? The reason for this is that we have addressed here the interface between
Paf1C and the transcribing polymerase, whereas insights into the mechanisms of chromatin
transcription will only come from a structural analysis of the interface of Paf1C with
nucleosomes and chromatin-associated factors. This poses a formidable challenge for the future.
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Appendix
Supplementary Matrial 1
Transcription elongation assay
To analyze whether Paf1C influences the Pol II transcription, the in vitro transcription elongation
assay was performed.  Two types of tailed template were used in this study (Table 8). One was
designed based on His4 gene (Table 8, RNA: FAM-RNA-20, template DNA: TA-1-tempalte
DNA, non-template DNA: TA-1-nontemplate DNA), and we refer it to ‘elongation template’.
The other one template used was GK-TA-pML5 template DNA buried AAAAAAA sequence,
which could induce TFIIS cleavage activity (Table 8, RNA: FAM-GK-RNA-20, template DNA:
GK-TA-pML5 template DNA, non-template DNA: GK-TA-pML5 nontemplate DNA), and we
refer this to ‘backtracked template’. Neither Paf1C nor Paf1C together with TFIIS alter the Pol II
transcription using both templates, even Paf1C was at high concentration (Supplementary Figure
1).
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Supplementary Figure 1: Transcription elongation assay in vitro. In panel a and b, elonagation
template was used, while in panel c and d, backtracked template was used. When TFIIS is absent (panel a
and c) or present (panel b and d), Paf1C doesn’t facilitate the Pol II transcription elongation in vitro.
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Supplementary Figure 2
Supplementary Figure 2: Crosslinking analysis of Paf1C. a, Coomassie-stained SDS-PAGE analysis
of BS3 cross-linker titration. A fixed amount of purified Paf1 complex was mixed with increasing
amounts of BS3 cross-linker. Gel was cropped to the largest subunit Ctr9. Successfully cross-linked Paf1
complex migrates at a higher molecular weight. 0.1 mM BS3 was chosen for final sample preparation. b,
Model of interactions within Paf1C. The circles represent the size of subunits. The solid lines show the
interaction obtained from XL-MS results. The grey shading indicates the numbers of observed cross-
links. c, Network diagrams of unique cross-links of Paf1 complex. Observed inter-links and intra-links
between are colored in dark cyan and purple, respectively.
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Supplementary Figure 3
Supplementary Figure 3: Cryo-EM reconstitution of Pol II-Paf1C-TFIIS. a, Angular distribution of
Pol II-Paf1C-TFIIS Cryo-EM single particle reconstruction. Red dots indicate at least one particle was
assigned within 1° of the point. Black shading indicates the number of particles assigned to a given view.
b, The overall resolution is estimated to be 5.5 Å on the basis of the gold-standard Fourier Shell
Correlation (FSC) criteria of 0.143. c, Top, front and front-side view of unsharpened Pol II-Paf1C-TFIIS
reconstruction colored by local resolution.
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Supplementary Table 1: Summary of various recombined Paf1 complexes.
Subunit
Name
Ctr9
(1-1077 aa)
Leo1
(1-464 aa)
Paf1
(1-445 aa)
Cdc73
(1-393 aa)
Rtf1
(1-558 aa)
Paf1C 1-1077 aa 1-464 aa 1-445 aa 1-393 aa 1-558 aa
Paf1C-Ctr9-∆C913 1-913 aa 1-464 aa 1-445 aa 1-393 aa 1-558 aa
Paf1C-Ctr9-∆C913-
∆Rtf1
1-913 aa 1-464 aa 1-445 aa 1-393 aa -
core Paf1C-
Rtf1∆N441
1-913 aa 118-376 aa 1-360 aa 1-393 aa 442-558 aa
core Paf1C 1-913 aa 118-376 aa 1-360 aa 1-393 aa -
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Supplementary Table 2: High-confidence crosslinks of Paf1C.
Residue Residue
Link type Protein a Protein b protein a protein b Max of Score
Inter Ctr9 Rtf1 166 483 9.690369833
Inter Ctr9 Rtf1 180 495 7.782516056
Inter Ctr9 Rtf1 235 517 7.4867824
Inter Ctr9 Rtf1 239 510 7.954677021
Inter Ctr9 Rtf1 497 530 9.801342913
Inter Ctr9 Leo1 432 369 10.06803389
Inter Ctr9 Leo1 552 369 9.774690718
Inter Ctr9 Paf1 235 93 11.24488773
Inter Ctr9 Paf1 239 93 9.879426069
Inter Ctr9 Paf1 232 109 22.06098022
Inter Ctr9 Paf1 232 114 25.02227639
Inter Ctr9 Paf1 235 109 5.559090918
Inter Ctr9 Paf1 450 109 8.03574037
Inter Ctr9 Paf1 620 12 12.11918641
Inter Ctr9 Paf1 626 12 5.725842151
Inter Ctr9 Paf1 765 12 12.79048499
Inter Ctr9 Paf1 813 12 8.074687909
Inter Ctr9 Cdc73 427 226 9.076238039
Inter Ctr9 Cdc73 427 366 5.029188389
Inter Ctr9 Cdc73 432 226 14.27490548
Inter Ctr9 Cdc73 636 218 5.272458743
Inter Ctr9 Cdc73 671 226 8.798602876
Inter Rtf1 Leo1 439 369 6.754487332
Inter Rtf1 Paf1 473 341 13.79048499
Inter Rtf1 Paf1 510 109 10.80134291
Inter Rtf1 Paf1 510 114 10.57186521
Inter Rtf1 Paf1 517 109 17.85387196
Inter Rtf1 Paf1 517 137 11.56066731
Inter Rtf1 Paf1 522 109 8.761953897
Inter Leo1 Paf1 122 215 18.60032628
Inter Leo1 Paf1 122 241 12.25806092
Inter Leo1 Paf1 122 320 12.74232143
Inter Leo1 Paf1 122 324 23.45593196
Inter Leo1 Paf1 142 324 13.34678749
Inter Leo1 Paf1 192 352 22.35359627
Inter Leo1 Paf1 225 137 6.448550002
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Residue Residue
Link type Protein a Protein b protein a protein b Max of Score
Inter Leo1 Paf1 285 215 20.83564714
Inter Leo1 Paf1 298 137 6.014573526
Inter Leo1 Paf1 316 283 15.40560745
Inter Leo1 Paf1 316 352 19.19382003
Inter Leo1 Paf1 337 283 13.8068754
Inter Leo1 Paf1 337 352 7.879426069
Inter Leo1 Cdc73 369 226 16.1700533
Inter Paf1 Cdc73 352 199 13.67778071
Intra Ctr9 Ctr9 356 367 14.82390874
Intra Ctr9 Ctr9 456 235 7.91721463
Intra Ctr9 Ctr9 497 530 20.02181948
Intra Ctr9 Ctr9 552 760 15.31785492
Intra Ctr9 Ctr9 620 626 5.543633967
Intra Ctr9 Ctr9 671 677 6.170053304
Intra Ctr9 Ctr9 682 636 5.218244625
Intra Ctr9 Ctr9 793 759 15.97469413
Intra Ctr9 Ctr9 813 626 7.184422252
Intra Ctr9 Ctr9 909 839 6.8569852
Intra Ctr9 Ctr9 923 938 5.718966633
Intra Ctr9 Ctr9 929 938 5.555955204
Intra Ctr9 Ctr9 941 948 15.73282827
Intra Ctr9 Ctr9 999 938 6.350665141
Intra Ctr9 Ctr9 1005 997 5.752026734
Intra Ctr9 Ctr9 1012 999 6.104025268
Intra Ctr9 Ctr9 1012 1005 8.040005162
Intra Ctr9 Ctr9 1012 1027 9.653647026
Intra Rtf1 Rtf1 33 131 11.87942607
Intra Rtf1 Rtf1 87 116 10.72815839
Intra Rtf1 Rtf1 131 138 12.89619628
Intra Rtf1 Rtf1 138 131 6.829738285
Intra Rtf1 Rtf1 162 170 5.496209317
Intra Rtf1 Rtf1 391 407 9.349692477
Intra Rtf1 Rtf1 391 460 11.95860731
Intra Rtf1 Rtf1 401 390 10.36552273
Intra Rtf1 Rtf1 401 412 17.00524306
Intra Rtf1 Rtf1 412 401 12.79588002
Intra Rtf1 Rtf1 412 432 9.129011186
Intra Rtf1 Rtf1 422 407 8.258848401
Intra Rtf1 Rtf1 439 391 13.63264408
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Residue Residue
Link type Protein a Protein b protein a protein b Max of Score
Intra Rtf1 Rtf1 439 401 16.78515615
Intra Rtf1 Rtf1 439 412 5.872895202
Intra Rtf1 Rtf1 439 450 13.32148162
Intra Rtf1 Rtf1 439 457 6.485452247
Intra Rtf1 Rtf1 439 460 10.38510278
Intra Rtf1 Rtf1 449 432 6.943095149
Intra Rtf1 Rtf1 449 457 5.298432015
Intra Rtf1 Rtf1 449 460 20.13846559
Intra Rtf1 Rtf1 449 474 13.5654311
Intra Rtf1 Rtf1 457 460 15.37882372
Intra Rtf1 Rtf1 457 473 10.18442225
Intra Rtf1 Rtf1 460 450 9.596879479
Intra Rtf1 Rtf1 460 473 11.47886192
Intra Rtf1 Rtf1 474 450 12.39147397
Intra Rtf1 Rtf1 474 460 19.86646109
Intra Rtf1 Rtf1 483 473 9.91721463
Intra Rtf1 Rtf1 495 473 5.002613616
Intra Rtf1 Rtf1 503 510 13.73518218
Intra Rtf1 Rtf1 510 473 10.27572413
Intra Rtf1 Rtf1 510 522 5.823908741
Intra Leo1 Leo1 298 305 12.51855737
Intra Leo1 Leo1 331 337 12.32148162
Intra Leo1 Leo1 337 305 10.21824463
Intra Leo1 Leo1 337 332 5.578396073
Intra Leo1 Leo1 355 369 10.97469413
Intra Leo1 Leo1 369 305 6.709965389
Intra Leo1 Leo1 369 337 10.1739252
Intra Paf1 Paf1 137 109 6.850780887
Intra Paf1 Paf1 137 170 9.463441557
Intra Paf1 Paf1 170 180 7.677780705
Intra Paf1 Paf1 241 212 5.614393726
Intra Cdc73 Cdc73 124 2 6.026872146
Intra Cdc73 Cdc73 194 205 21.03011836
Intra Cdc73 Cdc73 226 205 15.24336389
Intra Cdc73 Cdc73 226 218 7.540607512
Intra Cdc73 Cdc73 236 226 15.61978876
Intra Cdc73 Cdc73 236 304 14.31425826
Intra Cdc73 Cdc73 368 371 11.7212464
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Supplementary Table 3
Supplementary Table 3: High-confidence crosslinks of Pol II-Paf1C-TFIIS complex.
Type of
crosslinking  Protein a
Protein
b
Residue
protein a
Residue
protein b
Count of
Spectrum 1
Max of
Score 1
Count of
Spectrum 2
Max of
Score 2
Distance
(Å)/Domains
Pol II-Pol II Rpb1 Rpb11 368 37 6 11.54060751 4 11.17198494 20.2
Pol II-Pol II Rpb1 Rpb11 644 26 53 12.15428198 51 13.92445304 18.5
Pol II-Pol II Rpb1 Rpb11 644 62 4 14.31785492 4 15.97061622 18.4
Pol II-Pol II Rpb1 Rpb2 2 886 2 7.785156152 2 11.59006688 30.9
Pol II-Pol II Rpb1 Rpb2 2 934 4 13.47366072 4 15.01818139 39.2
Pol II-Pol II Rpb1 Rpb2 34 1183 3 5.534617149 5 5.772113295 14.8
Pol II-Pol II Rpb1 Rpb2 323 934 4 7.946921557 3 8.744727495 34.8
Pol II-Pol II Rpb1 Rpb2 1093 227 7 16.92811799 7 16.86327943 20.9
Pol II-Pol II Rpb1 Rpb2 1093 228 3 9.876148359 2 13.1260984 21
Pol II-Pol II Rpb1 Rpb2 1093 507 6 14.77469072 5 15.03715732 21.2
Pol II-Pol II Rpb1 Rpb2 1102 507 21 11.60730305 19 12.77989191 17.6
Pol II-Pol II Rpb1 Rpb2 1112 507 7 12.84466396 11 13.01412464 18.9
Pol II-Pol II Rpb1 Rpb2 1262 270 6 14.23210238 7 15.22257318 21.8
Pol II-Pol II Rpb1 Rpb4 15
1
(unstructured) 4 19.73754891 3 16.55129368
Pol II-Pol II Rpb1 Rpb4 129
1
(unstructured) 4 14.00921731 5 12.79317412
Pol II-Pol II Rpb1 Rpb4 129
2
(unstructured) 2 13.08039898 2 12.77989191
Pol II-Pol II Rpb1 Rpb5 15 171 2 11.69897 4 10.82390874 20.6
Pol II-Pol II Rpb1 Rpb5 129 161 5 8.066006836 7 7.958607315 21.8
Pol II-Pol II Rpb1 Rpb5 129 171 28 12.75448733 26 12.26841123 15
Pol II-Pol II Rpb1 Rpb5 938 152 3 5.987162775 6 7.288192771 19.8
Pol II-Pol II Rpb1 Rpb5 938 201 3 6.448550002 5 9.057495894 15.5
Pol II-Pol II Rpb1 Rpb5 941 152 4 7.353596274 6 7.583359493 18.3
Pol II-Pol II Rpb1 Rpb5 941 201 7 8.07007044 7 6.642065153 13.3
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Type of
crosslinking  Protein a
Protein
b
Residue
protein a
Residue
protein b
Count of
Spectrum 1
Max of
Score 1
Count of
Spectrum 2
Max of
Score 2
Distance
(Å)/Domains
Pol II-Pol II Rpb1 Rpb5 1003 197 4 10.89962945 4 11.87614836 20.3
Pol II-Pol II Rpb1 Rpb6 15
67
(unstructured) 3 3.798602876 4 6.187755303
Pol II-Pol II Rpb1 Rpb6 15 72 15 8.052566278 14 8.560667306 17.8
Pol II-Pol II Rpb1 Rpb6 129
67
(unstructured) 7 7.835647144 6 8.184422252
Pol II-Pol II Rpb1 Rpb6 1003 72 2 9.07211659 2 10.26280736 19.4
Pol II-Pol II Rpb1 Rpb6 1003 76 3 8.288192771 3 7.232844134 13.9
Pol II-Pol II Rpb1 Rpb8 977 136 3 7.844663963 2 8.522878745 13.3
Pol II-Pol II Rpb1 Rpb9 1093 93 7 16.31069114 6 14.32422166 16.2
Pol II-Pol II Rpb2 Rpb10 191
68
(unstructured) 4 6.698970004 4 7.735182177
Pol II-Pol II Rpb2 Rpb10 813 59 12 9.91721463 8 13.51427857 14
Pol II-Pol II Rpb2 Rpb3 191 149 3 7.111259039 4 8.89279003 13.5
Pol II-Pol II Rpb2 Rpb9 227 93 8 11.03668449 3 8.305394801 16.2
Pol II-Pol II Rpb3 Rpb10 149
68
(unstructured) 4 7.73754891 5 6.505845406
Pol II-Pol II Rpb3 Rpb11 253 37 2 8.075720714 2 9.321481621 14.5
Pol II-Pol II Rpb3 Rpb12 149 37 4 12.79048499 3 12.24260397 15.2
Pol II-Pol II Rpb4 Rpb5
1
(unstructured) 171 3 15.4723701 4 14.84466396
Pol II-Pol II Rpb4 Rpb5
2
(unstructured) 171 3 14.81247928 2 14.54060751
Pol II-Pol II Rpb4 Rpb6
1
(unstructured) 72 2 7.806875402 2 7.714442691
Pol II-Pol II Rpb5 Rpb6 171
67
(unstructured) 9 6.177178355 7 5.123205024
Pol II-Pol II Rpb5 Rpb6 171
70
(unstructured) 7 12.23062267 10 11.43415218
Pol II-Pol II Rpb5 Rpb6 171 72 16 12.76700389 19 12.83564714 16.1
Pol II-Pol II Rpb6 Rpb7
67
(unstructured) 73 7 13.86327943 6 7.59345982
Pol II-Pol II Rpb6 Rpb7 70 73 9 13.08565684 9 13.16052195
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Type of
crosslinking  Protein a
Protein
b
Residue
protein a
Residue
protein b
Count of
Spectrum 1
Max of
Score 1
Count of
Spectrum 2
Max of
Score 2
Distance
(Å)/Domains
(unstructured)
Pol II-Pol II Rpb6 Rpb7 72 73 24 16.89619628 24 15.8096683 17.6
Pol II-TFIIS TFIIS Rpb1 196 1217 12 22.77728353 9 20.98716278 16.4
Pol II-TFIIS TFIIS Rpb1 250 705 2 5.300162274 2 6.364516253 13.9
Pol II-TFIIS TFIIS Rpb1 273 1290 2 9.077793723 2 8.508638306 15.9
Pol II-TFIIS TFIIS Rpb1 278 1093 2 9.735182177 2 14.01954211 25.2
Pol II-TFIIS TFIIS Rpb1 278 1290 4 16.87942607 4 18.91721463 19.4
Pol II-Paf1C Ctr9 Rpb1 443 34 2 5.032452024 3 6.378823718 Clamp_Core
Pol II-Paf1C Ctr9 Rpb3 749 199 4 19.91009489 4 18.52287875 Rpb3
Pol II-Paf1C Rtf1 Rpb2 473 344 2 19.8728952 4 9.565431096 Lobe
Pol II-Paf1C Leo1 Rpb1 369 101 2 11.69464863 2 7.145693958 Clamp_Head
Pol II-Paf1C Leo1 Rpb1 369 1102 4 7.821023053 5 7.358525889 Cleft
Pol II-Paf1C Leo1 Rpb2 298 606 4 6.920818754 3 10.23657201 External 2
Pol II-Paf1C Leo1 Rpb2 302 606 5 7.171984936 8 6.632644079 External 2
Pol II-Paf1C Leo1 Rpb2 305 246 3 12.00086946 3 10.66354027 Lobe
Pol II-Paf1C Leo1 Rpb2 305 606 8 9.343901798 5 9.619788758 External 2
Pol II-Paf1C Leo1 Rpb2 332 87 6 14.59345982 3 8.866461092 Protrusion
Pol II-Paf1C Leo1 Rpb2 332 353 5 8.785156152 3 7.354577731 Lobe
Pol II-Paf1C Leo1 Rpb2 337 87 8 13.45222529 9 16.16052195 Protrusion
Pol II-Paf1C Leo1 Rpb2 337 133 2 12.69680394 2 8.407823243 Protrusion
Pol II-Paf1C Leo1 Rpb2 337 148 3 9.528708289 4 12.4828041 Protrusion
Pol II-Paf1C Leo1 Rpb2 337 228 5 13.36552273 6 11.82102305 Lobe
Pol II-Paf1C Leo1 Rpb2 337 246 4 10.61261017 3 11.82390874 Lobe
Pol II-Paf1C Leo1 Rpb2 337 270 2 9.93930216 2 10.24412514 Lobe
Pol II-Paf1C Leo1 Rpb2 337 277 2 7.448550002 5 9.13430394 Lobe
Pol II-Paf1C Leo1 Rpb2 337 344 4 11.90657831 5 12.32148162 Lobe
Pol II-Paf1C Leo1 Rpb2 337 353 4 10.4710833 4 8.576754126 Lobe
Pol II-Paf1C Leo1 Rpb2 337 358 3 9.838631998 3 10.08196966 Lobe
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Type of
crosslinking  Protein a
Protein
b
Residue
protein a
Residue
protein b
Count of
Spectrum 1
Max of
Score 1
Count of
Spectrum 2
Max of
Score 2
Distance
(Å)/Domains
Pol II-Paf1C Leo1 Rpb2 337 422 2 6.838631998 2 8.628932138 Protrusion
Pol II-Paf1C Leo1 Rpb2 337 426 2 7.696803943 2 7.801342913 Protrusion
Pol II-Paf1C Leo1 Rpb2 337 445 3 12.25181197 4 12.86327943 Protrusion
Pol II-Paf1C Leo1 Rpb2 337 451 4 11.03105032 3 11.39685563 Protrusion
Pol II-Paf1C Leo1 Rpb2 351 87 2 5.943095149 2 5.474955193 Lobe
Pol II-Paf1C Leo1 Rpb2 351 344 4 5.46470588 5 5.66756154 Lobe
Pol II-Paf1C Leo1 Rpb2 353 353 3 8.07007044 4 9.903089987 Lobe
Pol II-Paf1C Leo1 Rpb2 355 228 2 15.46852108 4 17.04383157 Lobe
Pol II-Paf1C Leo1 Rpb2 355 277 3 18.22402567 3 21.03668449 Lobe
Pol II-Paf1C Leo1 Rpb2 355 344 5 6.312471039 4 7.764471553 Lobe
Pol II-Paf1C Leo1 Rpb2 369 87 3 14.8096683 2 18.65364703 Protrusion
Pol II-Paf1C Leo1 Rpb2 369 228 13 26.33535802 12 24.61083392 Lobe
Pol II-Paf1C Leo1 Rpb2 369 270 13 18.4100504 13 19.22112553 Lobe
Pol II-Paf1C Leo1 Rpb2 369 277 9 19.6716204 13 22.58169871 Lobe
Pol II-Paf1C Leo1 Rpb2 369 344 7 14.86646109 9 13.25727487 Lobe
Pol II-Paf1C Leo1 Rpb2 369 353 2 7.560667306 2 6.235823868 Lobe
Pol II-Paf1C Leo1 Rpb2 369 426 7 12.83564714 10 11.95467702 Protrusion
Pol II-Paf1C Leo1 Rpb2 369 471 3 9.943095149 2 10.0259491 Fork
Pol II-Paf1C Leo1 Rpb2 369 865 3 23.09582563 2 18.44977165 Wall
Pol II-Paf1C Paf1 Rpb2 109 87 4 17.20273246 5 13.99567863 Protrusion
Pol II-Paf1C Paf1 Rpb2 114 451 3 11.19859629 2 9.344861565 Protrusion
Pol II-Paf1C Paf1 Rpb2 320 353 2 9.681936665 3 7.540607512 Lobe
Pol II-Paf1C Cdc73 Rpb11 205 55 4 12.87942607 4 11.79860288 Rpb11
Pol II-Paf1C Cdc73 Rpb11 218 55 10 10.79860288 10 10.9788107 Rpb11
Pol II-Paf1C Cdc73 Rpb11 236 55 2 6.080398976 2 17.87942607 Rpb11
Pol II-Paf1C Cdc73 Rpb11 385 55 2 6.126098402 3 6.809668302 Rpb11
Pol II-Paf1C Cdc73 Rpb2 194 451 3 17.27164622 5 14.58169871 Protrusion
Pol II-Paf1C Cdc73 Rpb3 263 199 3 15.28399666 3 14.34775366 Rpb3
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Type of
crosslinking  Protein a
Protein
b
Residue
protein a
Residue
protein b
Count of
Spectrum 1
Max of
Score 1
Count of
Spectrum 2
Max of
Score 2
Distance
(Å)/Domains
Paf1C-TFIIS Leo1 TFIIS 331 78 7 7.42945706 6 6.730487056 Domain I
Paf1C-TFIIS Leo1 TFIIS 331 80 3 7.844663963 3 6.8569852 Domain I
Paf1C-Paf1C Ctr9 Cdc73 427 226 2 6.027334408 3 9.510041521
Paf1C-Paf1C Ctr9 Cdc73 427 263 4 8.211124884 4 9.567030709
Paf1C-Paf1C Ctr9 Cdc73 427 385 5 12.21041929 4 12.63451202
Paf1C-Paf1C Ctr9 Cdc73 432 194 7 10.40011693 6 13.9625735
Paf1C-Paf1C Ctr9 Cdc73 432 282 3 11.82390874 3 11.07987667
Paf1C-Paf1C Ctr9 Cdc73 432 385 3 9.749579998 3 8.638272164
Paf1C-Paf1C Ctr9 Cdc73 443 263 4 7.500312917 4 7.853871964
Paf1C-Paf1C Ctr9 Cdc73 636 212 7 7.336299075 6 10.01099538
Paf1C-Paf1C Ctr9 Cdc73 636 218 7 12.30451832 6 10.45842076
Paf1C-Paf1C Ctr9 Cdc73 636 226 7 7.410050399 5 11.62342304
Paf1C-Paf1C Ctr9 Cdc73 636 385 3 20.66354027 4 17.4202164
Paf1C-Paf1C Ctr9 Cdc73 671 205 4 12.46852108 3 10.94692156
Paf1C-Paf1C Ctr9 Cdc73 671 212 3 7.294992041 5 6.732828272
Paf1C-Paf1C Ctr9 Cdc73 671 218 2 6.779891912 2 8.484126156
Paf1C-Paf1C Ctr9 Cdc73 671 385 5 9.991399828 5 9.841637508
Paf1C-Paf1C Ctr9 Cdc73 760 185 4 10.86012091 3 10.57839607
Paf1C-Paf1C Ctr9 Cdc73 784 385 4 6.549750892 4 5.375717904
Paf1C-Paf1C Ctr9 Cdc73 793 371 2 14.75202673 2 10.51286162
Paf1C-Paf1C Ctr9 Cdc73 867 385 3 9.718966633 3 10.61083392
Paf1C-Paf1C Ctr9 Leo1 443 337 3 9.400116928 2 9.049148541
Paf1C-Paf1C Ctr9 Leo1 450 369 2 13.8728952 2 15.60906489
Paf1C-Paf1C Ctr9 Leo1 749 305 3 7.612610174 5 8.728158393
Paf1C-Paf1C Ctr9 Leo1 759 305 2 10.87614836 2 12.82102305
Paf1C-Paf1C Ctr9 Leo1 784 337 2 8.519993057 2 5.623423043
Paf1C-Paf1C Ctr9 Leo1 793 302 3 8.59345982 5 7.716698771
Paf1C-Paf1C Ctr9 Leo1 839 337 2 8.089909454 2 8.183096161
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Type of
crosslinking  Protein a
Protein
b
Residue
protein a
Residue
protein b
Count of
Spectrum 1
Max of
Score 1
Count of
Spectrum 2
Max of
Score 2
Distance
(Å)/Domains
Paf1C-Paf1C Ctr9 Paf1 180 81 14 15.47495519 15 14.24795155
Paf1C-Paf1C Ctr9 Paf1 180 341 2 5.338187314 2 5.009661145
Paf1C-Paf1C Ctr9 Paf1 232 109 21 16.92445304 22 19.82973828
Paf1C-Paf1C Ctr9 Paf1 232 114 8 13.07314329 9 13.91721463
Paf1C-Paf1C Ctr9 Paf1 232 137 3 5.806875402 2 6.504455662
Paf1C-Paf1C Ctr9 Paf1 235 109 3 7.463441557 3 7.728158393
Paf1C-Paf1C Ctr9 Paf1 239 93 23 9.066512712 23 9.950781977
Paf1C-Paf1C Ctr9 Paf1 239 109 3 12.6716204 3 14.67985371
Paf1C-Paf1C Ctr9 Paf1 443 109 2 9.188424994 2 10.37365963
Paf1C-Paf1C Ctr9 Paf1 443 137 4 11.60906489 3 11.20342567
Paf1C-Paf1C Ctr9 Paf1 450 109 11 18.3419886 12 16.02826041
Paf1C-Paf1C Ctr9 Paf1 450 114 4 16.39147397 4 15.81247928
Paf1C-Paf1C Ctr9 Paf1 450 137 5 10.76700389 5 15.57348874
Paf1C-Paf1C Ctr9 Paf1 456 109 5 10.37263414 6 11.21609642
Paf1C-Paf1C Ctr9 Paf1 456 114 4 13.84771166 3 13.22621356
Paf1C-Paf1C Ctr9 Paf1 620 12 19 10.38510278 15 9.311580178
Paf1C-Paf1C Ctr9 Paf1 626 12 35 7.596879479 25 8.160521953
Paf1C-Paf1C Ctr9 Paf1 793 170 6 8.663540266 5 8.978810701
Paf1C-Paf1C Ctr9 Paf1 813 12 5 8.085656843 5 11.09799711
Paf1C-Paf1C Ctr9 Paf1 839 180 2 5.732828272 3 5.498940738
Paf1C-Paf1C Ctr9 Rtf1 156 457 3 9.675717545 3 8.218244625
Paf1C-Paf1C Ctr9 Rtf1 156 473 3 11.02826041 2 11.4698003
Paf1C-Paf1C Ctr9 Rtf1 166 460 5 14.83564714 5 16.81815641
Paf1C-Paf1C Ctr9 Rtf1 166 473 6 8.55129368 6 10.82681373
Paf1C-Paf1C Ctr9 Rtf1 166 483 3 13.79860288 2 12.96657624
Paf1C-Paf1C Ctr9 Rtf1 166 495 4 8.056505484 4 7.787812396
Paf1C-Paf1C Ctr9 Rtf1 180 457 5 11.8096683 2 10.81247928
Paf1C-Paf1C Ctr9 Rtf1 180 495 11 17.72584215 5 15.10679325
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Type of
crosslinking  Protein a
Protein
b
Residue
protein a
Residue
protein b
Count of
Spectrum 1
Max of
Score 1
Count of
Spectrum 2
Max of
Score 2
Distance
(Å)/Domains
Paf1C-Paf1C Ctr9 Rtf1 196 473 3 14.61978876 3 17.01188716
Paf1C-Paf1C Ctr9 Rtf1 232 457 4 13.95078198 4 12.59516628
Paf1C-Paf1C Ctr9 Rtf1 232 460 5 18.79317412 5 19.97061622
Paf1C-Paf1C Ctr9 Rtf1 232 473 6 15.66354027 5 14.17457388
Paf1C-Paf1C Ctr9 Rtf1 232 474 4 14.37882372 4 17.51855737
Paf1C-Paf1C Ctr9 Rtf1 235 517 3 7.43062609 4 6.360513511
Paf1C-Paf1C Ctr9 Rtf1 239 508 4 16.00392635 4 12.67985371
Paf1C-Paf1C Ctr9 Rtf1 239 510 4 13.77469072 3 12.91009489
Paf1C-Paf1C Ctr9 Rtf1 274 530 7 14.10402527 4 13.80134291
Paf1C-Paf1C Ctr9 Rtf1 277 530 7 12.49485002 6 12.74232143
Paf1C-Paf1C Ctr9 Rtf1 367 457 2 12.326058 1 7.602059991
Paf1C-Paf1C Ctr9 Rtf1 443 280 2 7.600326279 2 7.223298816
Paf1C-Paf1C Ctr9 Rtf1 443 432 2 10.91009489 2 9.274905479
Paf1C-Paf1C Ctr9 Rtf1 443 450 3 10.39147397 2 9.519993057
Paf1C-Paf1C Ctr9 Rtf1 443 460 4 13.22257318 4 13.92081875
Paf1C-Paf1C Ctr9 Rtf1 443 473 2 10.96657624 2 12.43533394
Paf1C-Paf1C Ctr9 Rtf1 450 284 2 7.360513511 3 9.05207638
Paf1C-Paf1C Ctr9 Rtf1 450 457 3 10.94692156 4 11.86966623
Paf1C-Paf1C Ctr9 Rtf1 450 460 2 12.35359627 2 10.85078089
Paf1C-Paf1C Ctr9 Rtf1 450 473 4 19.05650548 4 21.48545225
Paf1C-Paf1C Ctr9 Rtf1 450 510 2 10.80410035 2 9.343901798
Paf1C-Paf1C Ctr9 Rtf1 456 517 7 15.41680123 7 12.13727247
Paf1C-Paf1C Ctr9 Rtf1 456 522 4 8.772113295 4 9.37675071
Paf1C-Paf1C Ctr9 Rtf1 456 530 5 19.20342567 5 18.26520017
Paf1C-Paf1C Ctr9 Rtf1 487 530 4 14.92811799 3 16.23732144
Paf1C-Paf1C Ctr9 Rtf1 496 530 3 11.26280736 4 15.48017201
Paf1C-Paf1C Ctr9 Rtf1 497 530 61 19.66756154 56 18.12959609
Paf1C-Paf1C Ctr9 Rtf1 749 284 5 8.774690718 4 8.657577319
96
Type of
crosslinking  Protein a
Protein
b
Residue
protein a
Residue
protein b
Count of
Spectrum 1
Max of
Score 1
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Spectrum 2
Max of
Score 2
Distance
(Å)/Domains
Paf1C-Paf1C Rtf1 Leo1 280 302 2 5.288192771 2 6.298432015
Paf1C-Paf1C Rtf1 Leo1 280 337 2 7.029188389 3 6.53313238
Paf1C-Paf1C Rtf1 Leo1 280 369 3 15.82973828 3 16.627088
Paf1C-Paf1C Rtf1 Leo1 450 337 2 9.88941029 3 8.239577517
Paf1C-Paf1C Rtf1 Leo1 460 369 3 17.00656377 3 17.09151498
Paf1C-Paf1C Rtf1 Leo1 510 337 3 13.12205305 3 11.30364361
Paf1C-Paf1C Rtf1 Paf1 256 109 2 11.60906489 2 8.809668302
Paf1C-Paf1C Rtf1 Paf1 256 114 3 8.231361899 3 7.534617149
Paf1C-Paf1C Rtf1 Paf1 457 114 3 20.75202673 4 19.19246497
Paf1C-Paf1C Rtf1 Paf1 460 90 2 12.56066731 3 9.832682665
Paf1C-Paf1C Rtf1 Paf1 460 109 3 15.38404995 3 16.28650946
Paf1C-Paf1C Rtf1 Paf1 460 114 3 10.53910216 2 15.10679325
Paf1C-Paf1C Rtf1 Paf1 460 137 2 6.463441557 3 8.935542011
Paf1C-Paf1C Rtf1 Paf1 473 109 3 17.8827287 3 17.15552282
Paf1C-Paf1C Rtf1 Paf1 474 90 2 16.99567863 2 18.73992861
Paf1C-Paf1C Rtf1 Paf1 495 90 3 14.9625735 3 12.22475374
Paf1C-Paf1C Rtf1 Paf1 495 114 3 7.616184634 2 9.124360063
Paf1C-Paf1C Rtf1 Paf1 508 90 11 14.47495519 8 10.25727487
Paf1C-Paf1C Rtf1 Paf1 510 109 13 15.75945075 13 15.11861534
Paf1C-Paf1C Rtf1 Paf1 510 114 7 14.20065945 6 15.26520017
Paf1C-Paf1C Rtf1 Paf1 517 109 19 12.7212464 21 15.79048499
Paf1C-Paf1C Rtf1 Paf1 517 114 7 12.24565166 7 12.1857524
Paf1C-Paf1C Rtf1 Paf1 522 109 2 10.83268267 3 9.016373713
Paf1C-Paf1C Rtf1 Paf1 530 109 2 10.14508698 2 9.621602099
Paf1C-Paf1C Rtf1 Paf1 530 114 3 14.10568394 4 14.22767829
Paf1C-Paf1C Leo1 Cdc73 305 194 3 10.74472749 3 10.1713401
Paf1C-Paf1C Leo1 Cdc73 337 385 3 14.14327111 3 13.4828041
Paf1C-Paf1C Leo1 Cdc73 369 205 3 13.4723701 3 11.13489603
97
Type of
crosslinking  Protein a
Protein
b
Residue
protein a
Residue
protein b
Count of
Spectrum 1
Max of
Score 1
Count of
Spectrum 2
Max of
Score 2
Distance
(Å)/Domains
Paf1C-Paf1C Leo1 Cdc73 369 371 2
13.1051303
4 2 16.97061622
Paf1C-Paf1C Leo1 Paf1 122 320 2 11.2873503 6 12.73282827
Paf1C-Paf1C Leo1 Paf1 156 295 6 18.99567863 9 15.70553377
Paf1C-Paf1C Leo1 Paf1 192 283 2 9.160521953 2 6.410050399
Paf1C-Paf1C Leo1 Paf1 225 167 11 14.31247104 11 15.34103516
Paf1C-Paf1C Leo1 Paf1 225 170 3 10.86012091 4 12.93930216
Paf1C-Paf1C Leo1 Paf1 225 295 5 11.2873503 5 13.70553377
Paf1C-Paf1C Leo1 Paf1 302 137 10 10.43179828 13 8.716698771
Paf1C-Paf1C Leo1 Paf1 302 283 2 5.89279003 4 6.872895202
Paf1C-Paf1C Leo1 Paf1 305 114 2 5.590066877 2 8.609064893
Paf1C-Paf1C Leo1 Paf1 305 137 9 10.61261017 11 11.64975198
Paf1C-Paf1C Leo1 Paf1 305 283 4 7.434152181 4 6.872895202
Paf1C-Paf1C Leo1 Paf1 316 283 8 18.27083521 11 14.93554201
Paf1C-Paf1C Leo1 Paf1 331 341 3 7.2915791 4 9.048176965
Paf1C-Paf1C Leo1 Paf1 332 283 2 8.54515514 4 7.847711656
Paf1C-Paf1C Leo1 Paf1 332 352 2 6.899629455 2 5.279840697
Paf1C-Paf1C Leo1 Paf1 337 109 7 15.84163751 6 15.92445304
Paf1C-Paf1C Leo1 Paf1 337 114 2 15.9788107 3 13.91009489
Paf1C-Paf1C Leo1 Paf1 337 137 4 14.05749589 4 13.55284197
Paf1C-Paf1C Leo1 Paf1 337 283 6 17.13846559 6 17.3990271
Paf1C-Paf1C Leo1 Paf1 337 307 4 7.70333481 3 9.872895202
Paf1C-Paf1C Leo1 Paf1 337 341 4 13.71669877 5 11.47495519
Paf1C-Paf1C Leo1 Paf1 337 352 18 12.88605665 11 14.36251027
Paf1C-Paf1C Leo1 Paf1 369 109 2 12.64975198 2 13.81530857
Paf1C-Paf1C Leo1 Paf1 369 320 3 9.707743929 5 16.03011836
Paf1C-Paf1C Leo1 Paf1 369 341 2 10.19654288 3 10.73048706
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Abbreviations
°C degree celsius
∆ deletion
Å ångström
aa amino acid(s)
APS ammonium persulfate
ATP adenosine 5′-triphosphate
bp base pair(s)
BS3 bis(sulfosuccinimidyl) suberate
BSA bovine serum albumine
Cdc73 cell division cycle 73
CID CTD interaction domain
cryo-EM cryo electron microscopy
CTD carboxy-terminal domain
CTR C-terminal repeat region of Spt5
Ctr9 CLN3 requiring 9
Da Dalton
DMSO Dimethyl sulfoxide
DRB 5,6-dichloro-1-b -D-ribofuranosylbenzimidazole
DSIF DRB sensitivity inducing factor
DTT dithiothreitol elongation
E. coli Escherichia coli
EC elongation complex
EDTA ethylene diamine tetraacetate
EM electron microscopy
FAM 5’ 6- fluorescein
FDR false discovery rate
g gram or gravitational acceleration on earth’s surface
GraFix gradient fixation
GTF transcription factor
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HCl hydrochloric acid
HEPES 2-[4-(2-hydroxyethyl)-1-piperazinyl]-ethanesulfonic acid
His Histidine
IPTG isopropyl ß-D-1-thiogalactopyranoside
k thousand
L liter
LB lysogeny broth
Leo1 left open reading frame 1
M molar
min minute(s)
MOPS 3-(N-morpholino)propanesulfonic acid
MW molecular weight
NA nucleic acid(s)
NCBI National Center for Biotechnology Information
NELF negative elongation factor
nt nucleotide
NTP nucleoside triphosphate open
OD600nm optical density at 600 nm
ORF open reading frame
P-TEFb positive transcription elongation factor b
pA poly-adenylation
Pa1fC Paf1 complex
Paf1 polymerase-associated factor 1
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PCR polymerase chain reaction
PEP plastid-encoded Pol
PHD plant homeodomain
PI protease inhibitor pre-initiation
PIC pre-initiation complex
Pol DNA-dependent RNA polymerase
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PTM post-translational modification
RNA ribonucleic acid(s)
rpm revolutions per minute
rRNA ribosomal RNA
Rtf1 restores TBP function 1
S. pombe Saccharomyce pombe
S. cerevisiae Saccharomyces cerevisiae
SDS sodium dodecyl sulfate
SEC super elongation complex
siRNA interfering RNA
snRNA small nuclear RNA
TAE tris-acetate-EDTA
TBE tris borate EDTA buffer
TBP TATA binding protein
TE tris-EDTA
TEMED N,N,N’,N’-tetramethylethylenediamine
TFII transcription factor II
Tris tris-(hydroxymethyl)-aminomethane
tRNA transfer RNA
TSS transcription start site
V volt
v/v volume per volume
w/v weight per volume
XFEL x-ray free electron laser
XL-MS chemical crosslinking coupled to mass spectrometry
YPD yeast extract peptone dextrose
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